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SUMMARY 
C-reactive protein (CRP) is a major acute phase protein in dogs characterized by low 
physiological levels, a marked and fast increase shortly after a systemic inflammatory 
stimulus, followed by quick normalization when no further stimulus is present. C-
reactive protein is thought to possess high diagnostic specificity, as it is only induced 
by proinflammatory hypercytokinaemia. These properties should facilitate the use of 
canine CRP as a marker of systemic inflammatory activity for routine diagnostic, 
monitoring and screening purposes. The published information on canine CRP strongly 
indicate that CRP can be applied for routine purposes, but major impediments 
hindering a wide-spread application in canine medicine seemed to exist. 
The objective of the thesis is to test the hypothesis that “Canine serum CRP 
measurements are applicable for routine purposes in canine medicine”. This overall 
hypothesis was tested stepwise by addressing the following four phases: 
 
PHASE I Analytical investigations 
PHASE II Overlap investigations 
PHASE III Clinical investigations 
PHASE IV Outcome and utility investigations 
 
The thesis consists of five chapters. In Chapter 1, the current knowledge of the 
properties of CRP as a molecule, an acute phase protein and as a possible useful 
parameter in canine medicine is reviewed. In Chapter 2, two assays for the 
determination of canine serum CRP are objectively evaluated, regarding analytical 
performance (Phase I). Chapter 3 assesses the apparent clinical performance of 
canine serum CRP measurements by means of overlap and clinical investigations 
(Phases II and III). In Chapter 4 an example of the possible positive effect of canine 
serum CRP measurements on the case management of an immune-mediated disease 
in dogs is reported (Phase IV). Finally, the results of the work performed in the four 
phases are discussed, concluded upon and perspectivated in Chapter 5. 
The final conclusion of the thesis based on available published material and the work of 
the thesis (Chapters 2, 3 and 4) is that serum CRP measurements are applicable for 
routine purposes in canine medicine. 
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SAMMENDRAG (DANISH SUMMARY) 
C-reaktivt protein (CRP) er et ”major” akut-fase protein hos hunde, kendetegnet ved et 
lavt normal-fysiologisk niveau, en markant stigning kort efter en systemisk 
inflammatorisk stimulus, efterfulgt af en hurtig normalisering når stimulationen er 
ophørt. C-reaktivt protein menes at have en høj diagnostisk specificitet, da det alene 
induceres af proinflammatorisk hypercytokinæmi. Disse egenskaber burde understøtte 
den rutinemæssige anvendelighed af CRP til diagnostiske, monitorerings- og 
screeningsmæssige formål. Den publicerede mængde af information vedrørende 
hundens CRP indikerer kraftigt at CRP kan anvendes til rutinemæssige formål, men 
større hindringer for dette og den generelle udbredelse af brugen af CRP, synes at 
eksistere. 
Formålet med denne afhandling er at teste hypotesen at ”Målinger af hundens CRP i 
serum er anvendeligt til rutinemæssige kliniske formål”. Denne overordnede hypotese 
blev testet trinvist, ved at adressere de følgende fire faser: 
 
FASE I Analytisk duelighed 
FASE II Diagnostisk kapacitet 
FASE III Klinisk anvendelighed 
FASE IV Praktisk værdi 
 
Afhandlingen består af fem kapitler. I Kapitel 1 bliver den tilgængelige viden omkring 
CRP’s egenskaber som molekyle, akut-fase protein og den mulige anvendelighed som 
para-klinisk parameter gennemgået. I Kapitel 2 bliver to tilgængelige målemetoder til 
bestemmelse af CRP i hundeserum evalueret objektivt mht. analytisk duelighed (Fase 
I). Kapitel 3 vurderer den tilsyneladende diagnostiske kapacitet og kliniske 
anvendelighed (Faserne II og III). I Kapitel 4 rapporteres et eksempel på den mulige 
positive effekt af CRP målinger på patient-håndteringen ved en immun-medieret lidelse 
hos hunde (Fase IV). Endelig bliver der i Kapitel 5 diskuteret, konkluderet og 
perspektiveret på baggrund af de opnåede resultater. 
Afhandlingens endelige konklusion, som baseres på tilgængelig viden omkring 
hundens CRP og de opnåede resultater (Kapitlerne 2, 3 og 4) er at målinger af 
hundens CRP i serum har praktisk værdi i rutinemæssige kliniske henseender. 
_____________________________________________________________________ 
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The acute phase proteins 
The inflammatory reaction in a given disease process is a non-specific response to one 
or more inflammatory stimuli. The classical signs of local inflammation are: tumor, 
rubor, calor, dolor and functio laesa and they appear independent of the cause of 
inflammation. The systemic response of an inflammatory process extensive enough to 
cause such encompasses a wide range of phenomena designated the acute phase 
response (APR), which is mainly mediated through proinflammatory hypercytokinaemia 
(Figure1). 
 
 
Figure 1. The local and general symptoms and the metabolic effects caused by systemic 
inflammation, mainly mediated through the proinflammatory cytokines Interleukin-1 (IL-1), IL-6 
and tumor necrosis factor. CRP; C-reactive protein. TSH; Thyroid stimulating hormone. ACTH; 
Adrenocorticotrophic hormone. ADH; Anti-diuretic hormone. Modified from Hansson (1996).  
 
A major property of the APR is the dramatic changes in several blood proteins known 
as acute phase proteins (APP) (Baumann and Gauldie, 1994), which are sub-grouped 
in 4 groups (major, intermediate, minor and negative) according to their kinetic 
properties during and after an acute phase response (Figure 2). In human and dogs, C-
reactive protein is a major APP, characterized by low physiological levels, a marked 
_____________________________________________________________________ 
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fast increase shortly after an inflammatory stimulus, followed by quick normalization in 
the absence of further inflammatory stimulus (Figure 2). The intermediate and minor 
APP have a more delayed response, whereas the negative APP are down-regulated 
during an acute phase response (Figure 2), excellently described in detail by others 
(Mackiewicz et al., 1993). 
 
 
Figure 2. The relative kinetics of the serum concentration of major, intermediate, minor and 
negative acute phase proteins, respectively during an acute phase response. C-reactive protein 
is a major acute phase protein in human and dogs. Modified from Gabay and Kushner (1999). 
 
The major APP have received most attention as bio-markers for the acute phase 
response due to the facilitating properties of low physiological levels, the fast incline, 
the marked rise in concentration during APR that eases detection and the fast decline 
after a ceased stimulus. 
The history of C-reactive protein 
C-reactive protein (CRP) was discovered in human acute phase serum as early as 
1930 (Tillet and Francis, 1930) and has become to play a major role in human 
medicine. The discovery of CRP was based upon observations on human acute phase 
serum agglutinating certain members of Pneumococcus spp. by binding to a C-
polysaccharide (the property that later gave CRP its name) (Tillet and Francis, 1930). 
_____________________________________________________________________ 
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The agglutinating factor was identified as a protein in 1941 (Abernethy and Avery, 
1941), where also antiserum to purified human CRP was produced in rabbits (MacLeod 
and Avery, 1941). Shortly thereafter human CRP was crystallized (McCarty, 1947) and 
in 1950 the first report of the medical applicability of CRP in monitoring rheumatic 
activity in rheumatic patients appeared (Anderson and McCarty, 1950). 
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Figure 3. The annual distribution of Medline registered papers including human (squares) and 
canine (triangles) C-reactive protein (CRP), respectively. [Medline search strings: (YEAR[pdat] 
AND CRP AND Human) and (YEAR[pdat] AND CRP AND (dog or canine)), respectively]. 
 
A canine analogue to the human CRP was investigated in canine acute phase sera in 
the 1960’s (Gotschlich, 1962; Dillman and Coles, 1966), canine CRP was isolated in 
1970 (Riley and Coleman, 1970) and quantification made possible in 1972 by use of 
specific anti-canine CRP antibodies (Riley and Zontine, 1972). However, it was not 
really until the mid-1980’s and early 1990’s that canine CRP was studied more 
thoroughly. Dogs were found applicable as human acute phase models, due to 
observed similarities between the kinetics of human and canine CRP during an APR 
(Caspi et al., 1984; Conner et al., 1988; Eckersall and Conner, 1988; Yamamoto et al., 
1992; Burton et al., 1994), for which they are also currently used (Higgins et al., 2003; 
Kumagai et al., 2004). Since the 1990’s there has been a relative small, but ongoing 
research in the field of canine CRP (Figure 3), beneficial to the knowledge of both 
human and canine CRP. The field of research on human CRP is formerly exploding 
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with a nearby exponential increase in annually published material, reaching a mere 
1000 Medline publications in 2003 (Figure 3). 
Biochemical properties of CRP 
C-reactive protein is a member of the pentraxin protein-family which is a 
phylogenetically ancient group of proteins found in both vertebrates and invertebrates 
(Robey and Liu, 1981; Baltz et al., 1982) with a conserved structure and a calcium 
dependent ligand function. All pentraxins consist of one type of subunit. For CRP five 
identical, non-covalently bound subunits are arranged in a planar pentagonal ring-
structure that can be visualized by electron-microscopy (Osmand et al., 1977; Caspi et 
al., 1984). Also the three dimensional structure of human CRP was determined, where 
the grooves for calcium- and ligand-binding can be identified (Shrive et al., 1996) 
(Figure 4).  
 
 
Figure 4. Molecular structure and morphology of human C-reactive protein (CRP). Negatively 
stained electron micrograph showing the typical pentameric disc-like structure face-on and side-
on (arrows) [a]. Ribbon diagram of the crystal structure, showing the two calcium atoms 
(spheres) in the ligand-binding site of each subunit [b]. Space-filling model of the CRP molecule, 
showing a single phosphocoline molecule located in the ligand-binding site of each subunit [c]. 
Modified from Pepys and Hirschfield (2003). 
 
The only major physico-chemical difference discovered between human and canine 
CRP consists of a glycosylation of two subunits of canine CRP, whereas human CRP 
is fully unglycosylated (Caspi et al., 1984). The molecular weight of canine CRP was 
estimated to be in the range of 100kDa (Caspi et al., 1984) and 155kDa (Yamamoto et 
al., 1992). Human CRP has been observed to have affinity to a wide range of 
molecules and interact with several types of cells, which are the basis for a wide range 
_____________________________________________________________________ 
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of hypotheses of the physiological properties of CRP, commented in a following 
section. The ligand-affinity of CRP is either Ca2+-dependent, Ca2+-independent or 
dependent on the previous binding of another ligand (in part summarized in Figure 5 
and Table 3). Several of these affinities have been confirmed for canine CRP also 
(Caspi et al., 1984; Fujise, 1992; Onishi et al., 1994) and the properties of canine and 
human CRP can be considered very much alike. 
 
 
 
Figure 5. The Ca2+-dependent and Ca2+-independent ligand-affinity of C-reactive protein (CRP). 
C1q; Complement factor C1q. Modified from Hansson (1996).  
 
Induction, release and regulation of CRP 
The kinetic properties of canine CRP during an acute phase response are 
characterized by a low concentration at normal homeostasis (Yamamoto et al., 1992; 
Yamamoto et al., 1994b; Otabe et al., 1998), a short lag-phase after the inflammatory 
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stimulus of around 4 hours (Caspi et al., 1984; Conner et al., 1988; Higgins et al., 
2003), reaching a peak in concentration after approximately 24 hours (Conner et al., 
1988; Yamamoto et al., 1992), and a quick normalization after ended inflammatory 
stimulus (Conner et al., 1988; Yamamoto et al., 1992; Hayashi et al., 2001). Thus, 
canine CRP has the properties of an almost “real-time” marker of the inflammatory 
activity during an acute phase response. 
The induction and regulation of the acute phase response is well studied in humans 
and seems to be a well orchestrated reaction, but so complex that many aspects still 
remain uncertain (Kushner et al., 1989; Suffredini et al., 1999).  
However, the liver was identified as the major site for production and release of acute 
phase proteins (Hurlimann et al., 1966; Kampschmidt and Upchurch, 1974; 
Wannemacher, Jr. et al., 1975; Kushner and Feldmann, 1978; Kushner et al., 1980) 
and interleukin-6 is considered the major inducing cytokine of the hepatic production of 
CRP (Koj, 1985; Castell et al., 1989; Kishimoto, 1989; Yamashita et al., 1994). 
Interleukin-1 and TNF-alpha that is traditionally also considered as major 
proinflammatory cytokines seem not to be able to induce the hepatic synthesis of CRP 
alone or in combination, but should still be considered as major co-working modulators 
(Pepys and Baltz, 1983; Koj, 1985; Kushner et al., 1989; Taylor et al., 1989; Dinarello, 
1997). A study on rabbits observed no presence of CRP in hepatocytes during normal 
homeostasis, followed by an increased expression and distribution of CRP-expressing 
hepatocytes over time after an appropriate inflammatory stimulus, concluding that CRP 
secretion was fully based on de novo-synthesis (Kushner and Feldmann, 1978).  
 
Table 1. Inflammatory cells with capability to produce some of the proinflammatory cytokines 
Interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF-alpha) Hansson (1996) 
Monocytes-Macrophages 
Granular leukocytes 
B- and T-lymphocytes 
Endothelial cells 
Nerve-cells 
Astrocytes 
Synovial cells  
Epithelial cells 
Mast cells 
Fibroblasts 
 
The major source of systemic IL-6 during the acute phase response is the local release 
to the blood-stream from monocytes-macrophages and granular leukocytes at the site 
of inflammation, but a wide range of other cells have the capability to release 
proinflammatory cytokines and thus induce the acute phase response (Table 1). 
There is also evidence for extrahepatic expression of C-reactive protein by various cell 
types (Table 2), but for none of them at levels of other than local significance and for 
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some, CRP is solely expressed on the cell surface (Kuta and Baum, 1986; Kolb-
Bachofen et al., 1995). This could indicate that CRP is not merely acting as a systemic 
inflammatory factor but also as a part of the local immune-response. Thus, as the 
hepatocytes are the only significant systemic source of CRP, severe end-stage liver-
disease could result in decreased release during an acute phase response, as it was 
observed for another canine APP, haptoglobin (Andersson et al., 1998).  
Finally, an important observation made when reviewing the literature on CRP is that no 
non-proinflammatory inducers of CRP expression and release have been identified, 
that could impair a high diagnostic specificity, when using CRP as a marker of elevated 
proinflammatory activity (i.e. an acute phase response). Comprehensive reviews of the 
regulatory mechanisms of CRP and the APR at the cellular and transcriptional levels 
are available for readers interested in further details (Moshage, 1997; Suffredini et al., 
1999; Volanakis, 2001). 
 
Table 2. Examples of extra-hepatic cells capable of C-reactive protein expression 
Cell-type Species References 
Peripheral blood mononuclear cells Human  (Murphy et al., 1991) 
 (Kolb-Bachofen et al., 1995) 
Peripheral blood lymphocytes Human  (Kuta and Baum, 1986) 
Renal cortical tubular epithelial cells Human  (Jabs et al., 2003) 
Alveolar macrophages Human 
Dog 
 (Dong and Wright, 1996) 
 (Casals et al., 1998) 
Epithelial cells of the respiratory tract Human  (Gould and Weiser, 2001) 
Kupffer cells Rat  (Egenhofer et al., 1993) 
 
Physiological properties of CRP 
C-reactive protein has been present and conserved through the evolution for at least 
500 million years, as it is also found in the “living fossil” Limulus polyphemus (Robey 
and Liu, 1981), so it has undoubtedly some beneficial function. The major question, 
though, is: What is the major function of CRP? A regular screening-process in the 
search for the physiological properties of CRP has been going on, resulting in massive 
amounts of information on the binding, inductive and interactive capacities of CRP 
(exemplified by Figure 4 and 6). This has then been a source for further investigations 
_____________________________________________________________________ 
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and especially for further speculations on the physiological properties of CRP, resulting 
in a very complex and unclear mixture of speculative and evidence-based statements. 
 
 
Figure 6. Different interactions of C-reactive protein (CRP). Modified from Hansson (1996). 
 
Molecular interactions 
One of the characteristic biochemical properties of pentraxins is the calcium-dependent 
ligand binding, but CRP also possess a calcium-independent affinity to certain 
molecules and affinities dependent on the previous binding to other ligands (ligand-
dependent affinity) (Table 3). 
Especially the ligand-dependent affinity to other key immunological molecules and 
receptors has been a source for further investigations on the role of CRP in the 
acquired cellular and humoral immune-response. 
Cellular interactions 
C-reactive protein modulates the function and activity of a wide range of cells (Table 4). 
The effect of CRP is mainly activation, but under some circumstances also inhibition. 
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Table 3. Examples of Ca2+-dependent, Ca2+-independent and ligand-dependent ligands for C-
reactive protein 
Type of ligand References 
Ca2+-dependent ligands 
 
Phosphocholines  (Volanakis and Wirtz, 1979) 
 (Gotschlich and Edelman, 1965) 
Chromatin (Histones)  (Du Clos et al., 1988) 
Lecithin  (Hokama et al., 1974) 
Lipoproteins  (Mookerjea et al., 1994) 
Ca2+-independent ligands  
Polycations (poly-lysine and poly-arginine)  (Siegel et al., 1975) 
 (Dougherty et al., 1991) 
Fibronectin  (Salonen et al., 1984) 
Galactose-rich glycoconjugates  (Uhlenbruck et al., 1981) 
Ligand-dependent ligands  
Complement factor C1q (activation)  (Agrawal et al., 2001) 
Fc-gamma receptors  (Bharadwaj et al., 1999) 
 
Table 4. Examples of the modulatory effect of C-reactive protein on various cells 
Cell type Modulation References 
Monocytes-Macrophages Activation by opsonization  (Pue et al., 1996) 
 Promote chemotaxi  (Han et al., 2004) 
 Increase endothelial adhesion  (Woollard et al., 2002) 
Neutrophils Inhibition of chemotaxi  (Shephard et al., 1990) 
 Inhibition of degranulation  (Filep and Foldes-Filep, 1989) 
 Inhibits endothelial adhesion  (Zouki et al., 1997) 
Mast cells Activation  (Fujimoto et al., 2003) 
Platelets Activation  (Fiedel et al., 1982) 
 Inhibition  (Filep et al., 1991) 
Vascular smooth muscle cells Activation  (Hattori et al., 2003) 
 
The ability of CRP to recognize pathogens on a molecular level and to mediate their 
elimination by recruiting the complement system and phagocytic cells makes it an 
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important constituent of the first line of innate host defence (Volanakis, 2001). 
Furthermore, the protein appears to play a role in the clearance of apoptotic, necrotic 
and injured host cells again by recognition on a molecular level, thus possibly 
contributing to restoration of normal structure and function, but also seemingly 
inhibiting induced autoimmunity by scavenging altered endogenous structures and 
molecules (Du Clos et al., 1994; Gershov et al., 2000). 
Thus, the physiological function of CRP would seem to be: Provide innate unspecific 
protection by recognition of potentially harmful foreign molecules and altered 
endogenous structures and molecules. 
Canine CRP as a clinical marker of systemic inflammation 
The concentration of serum CRP is used for routine diagnostic, prognostic and 
screening purposes in a wide range of inflammatory diseases in human medicine, and 
investigations of new applications are ongoing. The recent issue of CRP being an early 
marker or maybe even a mediator of atherothrombosis (Jialal et al., 2004) and 
atherosclerosis (Manolov et al., 2003) appear to be one of the main reasons for the 
marked increase in published material on human CRP in the recent years (Figure 3). In 
canine medicine, a routine use of CRP measurements is not widespread, despite the 
rather comprehensive knowledge of important similarities to human CRP, regarding 
biochemical and physiological properties and not least, the kinetics during an acute 
phase response. These similarities suggest a potential for clinical applicability within 
canine medicine of similar magnitude as for CRP in human medicine. 
CRP in healthy dogs 
All previous investigations on the CRP level in non-diseased dogs report a low 
concentration compared to levels found in relation to inflammatory activity (Caspi et al., 
1984; Caspi et al., 1987; Yamamoto et al., 1992; Yamamoto et al., 1993b; Burton et al., 
1994; Yamamoto et al., 1994b; Börngen, 1998; Kuribayashi et al., 2003), although, a 
relative large variation between the observed ranges of CRP concentrations in healthy 
dogs are seen, most likely due to the use of different locally produced assays (Table 5). 
The effect of age and sex on the CRP concentrations in healthy dogs were investigated 
in the larger of the studies, where no correlation were observed (Yamamoto et al., 
1994b; Kuribayashi et al., 2003). A single study on the circadian and long-term 
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variation of CRP could also not detect any systematic variation within individuals, but 
observed a difference in the homeostatic set-points of CRP between individuals (Otabe 
et al., 1998). 
 
Table 5. The observed ranges of C-reactive protein (CRP) concentrations in non-diseased dogs 
CRP range (mg/L) Number of dogs Assays References 
<5 20 ELISA local  (Caspi et al., 1984) 
<5 – 67 42 EIA local  (Caspi et al., 1987) 
0.2 – 0.8 20 ELISA local  (Yamamoto et al., 1992) 
2.4 – 30.0 66 ELISA local  (Yamamoto et al., 1993b) 
0.6 – 13.2 84 ELISA local  (Yamamoto et al., 1994b) 
5.9 – 28.7 44 TIA local  (Burton et al., 1994) 
0 – 70 50 ELISA local  (Börngen, 1998) 
0.8 – 16.4 10 ELISA local  (Otabe et al., 1998) 
1.5 – 18.9 144 ELISA local  (Kuribayashi et al., 2003) 
0.2 – 4.0 21 ELISA#  (Martínez-Subiela et al., 2004b) 
EIA; Electroimmunoassay. ELISA; Enzyme-linked immunosorbent assay. TIA; Turbidimetric 
immunoassay. #Phase-Range canine CRP, Tridelta, Kildare, Ireland. 
 
A final interesting aspect of CRP in healthy dogs is that several studies have reported 
raised CRP concentrations in the normo-physiological state of pregnancy in dogs 
(Eckersall et al., 1993; Concannon et al., 1996; Kuribayashi et al., 2003). In pregnant 
dogs, a marked increase in CRP was observed in the period of day 21-55 after the 
ovulation compared to non-pregnant bitches in the same stage of the estrous-cyclus. 
The increase in CRP was equivalent to that seen in an acute phase response, but the 
specific source of the stimulus remains unclear (Eckersall et al., 1993), although, it is 
most likely due to an inflammatory reaction to the embryonic implantation. 
Experimental studies 
Several experimental studies on canine CRP have investigated the canine acute phase 
response to various stimuli and various features of CRP as inflammatory marker. Many 
of the studies have been conducted to assess the applicability of the dog as a model 
for the human acute phase and CRP response. 
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Aseptic stimuli 
Experimental settings using aseptic induction of the acute phase response reported, as 
expected, that the acute phase response could be set-off from a wide variety of tissues 
using a wide variety of stimuli (Table 6). In addition, studies including various aseptic 
stimuli and various degrees of stimuli indicated that the relative CRP concentration 
reflected the relative degree of inflammatory activity (Otabe et al., 2000; Hayashi et al., 
2001). Hayashi et al. (2001) also detected an interesting and important age-
dependency of the increase in CRP after a variety of both aseptic and septic 
experimental inflammatory induction, where dogs under 3 months of age were 
observed to have a markedly lower response than dogs above 3 months of age after 
equivalent stimuli. This age-dependent aspect is important as it may impair the 
diagnostic sensitivity of CRP as an acute phase marker in very young dogs (Hayashi et 
al., 2001). Finally, a few of the studies compared the applicability of both CRP and 
complete blood cell count (CBC) concluding that a greater (Otabe et al., 2000) or 
equivalent (Yamashita et al., 1994; Burton et al., 1994) level of information on the 
inflammatory process could be derived from CRP compared to CBC in experimental 
aseptic inflammation. 
Septic stimuli 
A wide variety of studies on experimentally induced infections confirm the findings from 
the aseptic studies (Table 6). Furthermore, additional indications for CRP being a “real-
time” marker of the relative inflammatory activity could be derived from infectious 
studies: Experimental infections with agents with different incubation period or 
immunogenic nature was clearly reflected by the observed kinetics of the CRP level, 
where increased levels of CRP were seen simultaneously with the expected active 
periods of the disease and the relative level corresponded to the observed disease 
activity. (Caspi et al., 1987; Ndung'u et al., 1991; Rikihisa et al., 1994; Yamamoto et al., 
1994a; Martínez-Subiela et al., 2002). 
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Table 6. Examples of various stimuli and sites of application resulting in an elevated level of 
canine C-reactive protein in experimental studies 
Stimulus Application site References 
Aseptic   
Acetylic acid Gastric mucosa  (Otabe et al., 2000) 
Casein SC  (Caspi et al., 1987) 
Mineral oil Intra-bronchial  (Dillman and Coles, 1966) 
Talcum powder IP  (Dillman and Coles, 1966) 
Turpentine IM  (Yamashita et al., 1994) 
 SC  (Hayashi et al., 2001) 
- Surgical procedures   
 Gastrotomy  (Hayashi et al., 2001) 
 Ovariohysterectomy  (Hayashi et al., 2001) 
 (Burton et al., 1994) 
 (Yamamoto et al., 1992) 
 (Caspi et al., 1987) 
 (Yamamoto et al., 1993b) 
 Laparotomy  (Liu et al., 2000) 
 Sterile pericarditis  (Kumagai et al., 2004) 
 Elective orthopaedic surgery  (Caspi et al., 1987) 
 (Yamamoto et al., 1993b) 
 Aortic graft implant  (Conner et al., 1988) 
Septic   
Bordetella bronchiseptica Intra-bronchial  (Yamamoto et al., 1994a) 
Ehrlichia canis IV  (Rikihisa et al., 1994) 
 (Shimada et al., 2002) 
Endotoxin IV  (Higgins et al., 2003) 
Escherichia coli IV  (Hulton et al., 1985) 
Leptospira interrogans IP  (Caspi et al., 1987) 
Staphylococcus aureus SC  (Hayashi et al., 2001) 
Trypanosoma brucei IV  (Ndung'u et al., 1991) 
IM; intramuscular. IP; intraperitoneal. IV; intraveneous. SC; subcutaneous. 
 
Studies on spontaneously diseased dogs 
The clinical performance of a disease marker is best evaluated by controlled studies of 
patients recruited from the population where the marker is expected to be used 
(Bossuyt et al., 2003). Therefore, studies on spontaneously diseased dogs are 
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necessary to assess the applicability of CRP as a clinical useful marker of systemic 
inflammation in canine medicine. Several studies evaluating the clinical utility of canine 
CRP have been performed. The assessments of diagnostic accuracy may, although, 
be considered biased due to selection, as none of them are performed strictly as 
prospective randomized controlled studies. 
A high diagnostic sensitivity of serum CRP was observed in detecting systemic 
inflammation as defined by a significant number of circulating band neutrophils (Burton 
et al., 1994). A high diagnostic sensitivity and specificity of CRP in combination with 
band neutrophil count in the differentiation of pyometra and endometrial hyperplasia 
was observed in a controlled study (Fransson et al., 2004).  Eckersall et al. (1988) 
screened 155 dogs presented to their university hospital and found an increased CRP 
concentration in 67 dogs, all with identifiable inflammatory foci, indicating good 
predictive value of a positive result, as also reported by others (Riley and Zontine, 
1972; Börngen, 1998). Furthermore, the magnitude of the response seemed to 
correlate to certain groups of causes, which they interpreted as an ability to graduate 
the inflammatory activity by means of CRP measurements (Eckersall et al., 1988), as it 
was also concluded by several of the experimental studies. A study on canine 
leishmaniasis reported CRP as a measure to detect subclinical states of the disease 
(Martínez-Subiela et al., 2002). However, CRP seemed not to possess that feature in 
the detection of subclinical ehrlichiosis (Rikihisa et al., 1994; Shimada et al., 2002). 
Then again, a CRP response was found in the chronic phase of naturally occurring 
canine ehrlichiosis (Rikihisa et al., 1994). 
The relative CRP concentration seemed to correlate with the present disease activity 
and the severity or the prognosis of the diseased dogs in several studies; erosive vs. 
non-erosive arthritis (Caspi et al., 1987), metastatic vs. localized mammary neoplasia 
(Caspi et al., 1987), complicated vs. uncomplicated babesiosis (Matijatko and Kucer, 
2002), oedematous vs. necrotizing pancreatitis (Spillmann et al., 2002), the relative 
disease activity in inflammatory bowel disease (Jergens et al., 2003) and correspond to 
clinical improvement in dogs with various disorders (Yamamoto et al., 1993b). Two 
studies also evaluated CRP as an end-point marker of treatment efficiency with positive 
results (Jergens et al., 2003; Martínez-Subiela et al., 2003a). However, in other 
diagnostic entities CRP was observed not to be clinically applicable as a prognostic or 
disease severity marker; glomerulonephritis (Caspi et al., 1987) and as an end-point 
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marker in the assessment of the anti-inflammatory effect of n-3 fatty acids in dogs with 
pruritus (Nesbitt et al., 2003). 
Therapeutic modulation of the CRP acute phase response 
The indication that CRP reflects inflammatory activity in an almost “real-time” manner 
during the state of disease facilitates applicability as a marker of therapy efficiency. 
However, this suggested use of CRP requires that the response is not modulated or 
induced by therapy itself. Therapeutic modulation and induction of the CRP response is 
also an important issue for the use of CRP as a diagnostic marker of inflammation, as it 
could impair diagnostic sensitivity and specificity. Only a few, but very important reports 
on this issue on canine CRP are available. The most important observations were that 
neither short-term nor long-term high-dose steroid therapy induced a CRP response in 
healthy dogs (Martínez-Subiela et al., 2004b), steroid therapy did not modulate the 
CRP response compared to untreated controls in experimental Bordetella 
bronchiseptica infection (Yamamoto et al., 1994a) and neither did non-steroid anti-
inflammatory therapy of experimental Escherichia coli sepsis (Hulton et al., 1985). 
Finally, CRP was not compromised as a marker of inflammation in experimentally 
induced synovitis by carprofen, etodolac, meloxicam or butorphanol, in a controlled 
study on pain relief in dogs (Borer et al., 2003). Thus, CRP seems to be a stable 
marker of inflammation during various frequently used anti-inflammatory and 
immunomodulating therapies that is known to modulate or induce other important 
inflammatory markers, e.g. rectal temperature and CBC (Hulton et al., 1985; 
Yamamoto et al., 1994a). Interleukin-6 applied as a possible therapy to modulate 
bacterial invasion in experimental pancreatitis was reported to modulate the CRP 
response (Liu et al., 2000), as expected, because IL-6 is the main inducer of the acute 
phase response (see Introduction). Modulation by downregulation of the CRP response 
by the therapeutic group of statins was also reported in both dogs and human models 
for vasculitis (Strandberg et al., 1999; Kumagai et al., 2004). However, signs of a lower 
inflammatory activity during the state of disease was also detected in the treated group 
(Kumagai et al., 2004), suggesting that the CRP level may still reflect this activity 
during statin treatment. 
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Measuring canine CRP 
A key issue when assessing the applicability of a parameter for routine use is the 
general practicability, which especially includes assessment of the availability of 
reliable assays and the costs (regarding both time and economic expenses) of the 
different methods. 
Several canine-specific methods have been developed to quantify CRP, mainly used in 
scientific scales only in different specific studies: Capillary immuno-reaction (Riley and 
Zontine, 1972), sandwich enzyme-linked immunosorbent assay (ELISA) (Eckersall et 
al., 1989; Yamamoto et al., 1992), competitive ELISA (Börngen, 1998), slide reversed 
passive latex agglutination  (Yamamoto et al., 1994b), immunodiffusion  (Conner et al., 
1988; Yamamoto et al., 1992), electro-immunoassay (Caspi et al., 1984), quantitative 
capillary reversed passive latex agglutination (Tagata et al., 1996), laser nephelometric 
immunoassay (Onishi et al., 2000; Kumagai et al., 2004), time-resolved 
immunofluorometric assay (Parra et al., 2004) and immunoturbidimetric assay 
(Eckersall et al., 1991). A non-immuno enzyme-linked assay based on the ligand 
affinity of CRP to phosphorylcholine was also developed (Deegan et al., 2003). 
However, only a few quantitative canine CRP assays were made commercially 
available (a sandwich ELISA [Phase Range, Tridelta, Kildare, Ireland] and an 
immunoturbidimetric assay [K-assay, Kamiya Biomedical Company, Seattle, USA]), but 
none of them were independently evaluated for canine serum CRP determination for 
clinical use. Recently, although, an available semi-quantitative immuno-
chromatographic canine CRP method was validated (McGrotty et al., 2004). 
The possibility to perform heterologous determination of canine CRP have also been 
investigated, as heterologous determination has been reported to be fully valid for other 
canine parameters (Hoier and Jensen, 1993; Jensen et al., 2001), and could solve the 
problem of availability and maybe enhance cost- and time-effectiveness by the use of 
established human assays. Several reports on the cross-reactivity of canine CRP 
towards different polyclonal and monoclonal anti-human CRP antibodies exist and 
these observed either no cross-reactivity (Caspi et al., 1984; Maudsley and Pepys, 
1987; Yamamoto et al., 1993c; Börngen, 1998; Parra et al., 2002) or an undetermined 
degree of cross-reactivity insufficient for quantitative assay purposes (Gotschlich, 1962; 
Dillman and Coles, 1966; Riley and Coleman, 1970; Yamamoto et al., 1992; 
Yamamoto et al., 1993a; Concannon et al., 1996). Thus, the potential of using anti-
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human CRP antibodies for the determination of canine CRP remained an unclear 
matter.  
Preanalytical factors 
The preanalytic influence of sampling and handling procedures on the observed level 
of CRP have been addressed in a few canine studies, where the level was observed 
not to change significantly in a period of repetitive short-interval phlebotomies in a 
study of circadian fluctuations (Otabe et al., 1998) or as a result of administration of 
placebo or control material in studies on experimental infections (Rikihisa et al., 1994; 
Yamamoto et al., 1994a). 
For some of the canine specific CRP assays various postsampling preanalytical factors 
have been investigated, suggesting that the use of citrated plasma may decrease the 
CRP level (Martínez-Subiela et al., 2004a). Haemolysis, according to method, may 
alter the measured level of CRP compared to fresh serum samples (Eckersall et al., 
1991; Martínez-Subiela et al., 2004a). The use of ethyl-diamine tetra acetate or lithium 
heparine stabilized plasma seemed not to alter the measured level of CRP (Martínez-
Subiela et al., 2004a). Recent investigations reported that the use of gel-separator in 
blood containers may have a preanalytical influence on the measured level of human 
CRP of a magnitude important only at low levels (Anderson et al., 2003; Chang et al., 
2003; Anderson et al., 2004). In human medicine the observation of abnormal 
fluctuations of CRP at low levels may be indicating increased risk of chronic disease 
development (Kluft and de Maat, 2002). This correlation at low levels of CRP was not 
established in canine medicine and therefore, the influence of the gel-separator may be 
negligible for canine CRP. 
Finally, canine C-reactive protein was reported to possess useful storage properties 
with no significant change in immunoreactivity after storage overnight at 4˚C, up to 2 
months at -20˚C  (Dillman and Coles, 1966) and up to 4 months at -10˚C (Riley and 
Zontine, 1972) and may be assumed to be stable at storage temperatures below -70˚C 
(unpublished observations). The immunoreactivity of canine CRP is reported to be 
eliminated after 30 minutes at 70˚C (Dillman and Coles, 1966). 
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Clinical applicability of canine CRP measurements 
The knowledge of the properties of CRP, as a whole, indicates that an elevated level of 
serum CRP is consistent with an acute phase response, no matter the origin or nature 
of the stimulus. Furthermore, the relative level of CRP seems to reflect the relative 
activity of the inflammation during the state of disease, again without relation to the 
origin or nature of the stimulus. Thus, the CRP response doesn’t seem to depend on 
whether the inflammatory stimulus is of, e.g. aseptic, bacterial or viral nature, but rather 
on how destructive and proinflammatoric the stimulus is. The diagnostic sensitivity of 
CRP is facilitated by the properties of a major acute phase protein, with very low 
physiological concentrations compared to the consistent marked increase during an 
acute phase response.  Regarding diagnostic specificity, it seems that the only 
significant inducer of increased serum CRP levels is the proinflammatory cytokine IL-6, 
giving CRP the potential of being a diagnostically specific marker of proinflammatory 
hypercytokinaemia, i.e. an acute phase response. However, the diagnostic sensitivity 
as an inflammatory marker seemed to be impaired in very young dogs (< 3 months of 
age) (Hayashi et al., 2001) and diagnostic specificity impaired during mid-gestation of 
pregnant dogs (Eckersall et al., 1993; Concannon et al., 1996; Kuribayashi et al., 
2003). The most frequently used anti-inflammatory drugs did not compromise CRP as 
an inflammatory marker and the only therapeutic entities reported to modulate the CRP 
response seem to do this through a direct modulation of the inflammatory activity and 
therefore possibly not compromising CRP as a marker thereof. Finally, the influence of 
common preanalytical factors regarding sampling, handling and storage seem not to 
adversely affect routine applicability, and regarding storage, the properties are superior 
to that reported for cellular inflammatory markers (Vogelaar et al., 2002). 
Thus, the knowledge of CRP and the positive indications for its potential as a marker of 
inflammatory activity within different aspects of canine medicine is quite 
comprehensive. However, the review of the previous investigations of canine CRP also 
reveals that some areas of importance to an objective assessment of the applicability 
of CRP in canine medicine, lack attention. The lack of practical applicable validated 
quantitative assays for the determination of canine CRP seems to be the major 
impediment for the establishment of a routine use of CRP. In addition, if such assays 
can be identified, there will be a need for objectively derived clinical decision levels for 
different settings of clinical interest, e.g. for diagnostic, screening and monitoring 
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purposes. Finally, the utility of CRP compared to other well-established inflammatory 
markers in different clinical settings should be further investigated, as the knowledge 
on this field is still limited to a few studies. 
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Objectives, hypotheses and outline of the thesis 
It was the objective of the present thesis to solve the major issues that currently impair 
implementation of canine CRP as a routine parameter in canine medicine and to 
sustain the applicability of CRP measurements in canine medicine.  
The main hypothesis for the thesis was: 
• Canine serum CRP measurements are applicable for routine purposes in 
canine medicine. 
To facilitate the process of testing this hypothesis, the different aspects of the 
hypothesis were addressed in a stepwise manner. It has been suggested that the 
introduction of a diagnostic parameter for routine laboratory use should be done similar 
to the structured evolution of a new drug through a phase trial (Zweig and Robertson, 
1982; Fraser, 2001) going through the following phases: 
• Phase I Analytical investigations 
- Assessment of reliability and practicability characteristics 
• Phase II Overlap investigations 
- Assessment of values in health and disease 
• Phase III Clinical investigations 
- Evaluation of diagnostic sensitivity and specificity in clinical settings of 
interest 
• Phase IV Outcome and utility investigations 
- Assessment of whether individual (or community) gain advantage 
A test can then only be said to be truly applicable for routine purposes through 
acceptable and useful results throughout all phases of the trial, and at the bottom-line 
answering to the statement of Zweig and Robertson (1982): “A laboratory test is 
clinically useful only if it successfully answers a question of consequence to patient 
management”.  
The structure of this suggested phase trial was adopted throughout the thesis-projects 
and the corresponding phases were implemented as sub-hypotheses to assist testing 
the main hypothesis of the thesis. The sub-hypotheses were as follows: 
• Phase I 
- The analytical performance of commercially available assays (and 
available calibration material) can fulfil recognized objective analytical 
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performance standards, regarding imprecision, inaccuracy, total error 
and detection limit, thus determine canine CRP reliably in both the short- 
and long-term. 
• Phase II and III 
- Canine CRP measurements can  
 Discriminate between healthy dogs and different subpopulations 
of diseased dogs or 
 Discriminate between different subpopulations of diseased dogs.  
• Phase IV 
- Canine CRP measurements has a positive consequence on the case 
management of individuals or groups of individuals in canine medicine, 
e.g. by either 
 Improving the outcome of a clinical problem 
 Providing equivalent clinically useful information faster than 
established parameters 
 Providing equivalent clinically useful information more cost-
effective than established parameters 
In phase I (Chapter 2) a commercially available canine specific CRP sandwich ELISA 
(Paper I) and a human CRP turbidimetric immunoassay (CRP-TIA) (Paper II) were 
validated for the determination of canine serum CRP. In parallel the biological variation 
of canine serum CRP was investigated (Paper III) to establish objective analytical 
performance standards for imprecision, inaccuracy and total error for use in phase I, 
but also to provide valuable information for the clinical decision level for serially 
obtained CRP measurements and evaluation of the usefulness of population-based 
reference ranges. The successful validation of the human CRP-TIA for heterologous 
determination of canine CRP made it necessary to investigate the possibility to plan 
and implement a canine-specific internal quality control procedure for that assay (Paper 
IV). 
Phase II and III (Chapter 3) were completed by the establishment of a population 
based reference range for healthy dogs and an investigation of the clinical performance 
of CRP in discriminating between different diagnostic groups of clinical interest (Paper 
V). Finally, in phase IV (Chapter 4) a case-report on the use of CRP measurements in 
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a specific clinical setting provided additional evidence on the clinical benefits of canine 
CRP measurements on case-management (Paper VI). 
The overall results of this phase trial to test the applicability of serum CRP for routine 
purposes in canine medicine are discussed, concluded upon and put in perspective in 
Chapter 5. 
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Chapter 2 
 
 
PHASE I – ANALYTICAL INVESTIGATIONS 
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Summary
The purpose of this study was to evaluate a commercially
available enzyme-linked immunosorbent assay for determin-
ation of canine serum C-reactive protein (CRP). The con-
centration of CRP could be determined accurately and the
intra- and inter-assay coeﬃcients of variation were in the
range of 6.9–10.1 and 7.5–29.0%, respectively. This level of
imprecision between runs is usually considered unacceptable
for diagnostic purposes, but the overall results indicated that
the assay was useful in diﬀerentiating dogs suﬀering from
infections, from dogs suﬀering from various other diseases
(neoplastic diseases, endocrine/metabolic disorders), and heal-
thy dogs. The assay was also able to detect dynamic changes of
CRP during development and after cessation of spontaneous
occuring inﬂammatory stimuli in two clinical cases.
Introduction
Several studies identify canine serum C-reactive protein (CRP)
as an acute phase marker with a low physiological level and a
rapid increase with the onset of acute inﬂammation or tissue
destruction (Conner et al., 1988; Yamamoto et al., 1992;
Burton et al., 1994; Yamashita et al., 1994; Hayashi et al.,
2001). Additionally, CRP concentration seems to reﬂect the
underlying disease activity (Ndung’u et al., 1991; Yamamoto
et al., 1994a; Otabe et al., 2000), which together with the rapid
drop after ended inﬂammatory stimuli (Conner et al., 1988;
Burton et al., 1994), can make CRP useful for prognostic,
monitoring and diagnostic purposes.
Recently, a species-speciﬁc enzyme-linked immunosorbent
assay (ELISA) for canine serum CRP has become commer-
cially available. The aim of this study was to evaluate this
assay by means of imprecision, inaccuracy, detection limit
(DL), ability to detect dynamic changes and comparison of
CRP values in various groups of dogs.
Materials and Methods
Clinical assessment
Forty-six dogs were included in this part of the study.
Thirty-eight dogs were client-owned dogs presented at the
Small Animal Veterinary Teaching Hospital, Department of
Clinical Studies, The Royal Veterinary and Agricultural
University, Denmark, for various diagnostic, therapeutic or
prophylactic measures. Eight dogs were clinically healthy
beagle dogs from a research colony. All these dogs were
subjected to clinical examination and standard haematolog-
ical and clinical chemical proﬁles performed at our laborat-
ory (Jensen et al., 2001). Additional diagnostic testing on
each dog was conducted at the discretion of the individual
clinician (e.g. endocrine testing, biopsies, radiography, smears
or microbial testing).
Based on the above examinations and the ﬁnal clinical
diagnosis, the 46 dogs were retrospectively assigned to ﬁve
groups, i.e. clinically healthy dogs, dogs with neoplastic
diseases, dogs with infection, dogs with endocrine/metabolic
disorders and dogs with miscellaneous diseases not belonging
to any of the former groups. Speciﬁcally, clinically healthy
dogs should have unremarkable ﬁndings on clinical and
clinical pathological examination. Dogs with neoplastic dis-
eases had tumours that were cytologically and/or histologically
characterized as neoplastic. Dogs with infection had a patho-
gen identiﬁed that could be related to the pathological
ﬁndings. Dogs with endocrine/metabolic disorders had a ﬁnal
diagnosis that could be related to a hormone or metabolic
malfunction/disorder. Dogs with miscellaneous diseases had
various diagnoses and no clinical ﬁndings to associate them
with any of the other groups.
CRP dynamics
In experimental studies, CRP reportedly increases within the
ﬁrst 24 h following induction of an inﬂammatory response
(Otabe et al., 2000; Hayashi et al., 2001) and gradually
decline after cessation of the inﬂammatory stimuli (Yama-
moto et al., 1993; Hayashi et al., 2001). A clinical case of
acute mastitis caused by Pseudomonas aeruginosa in a 7-year-
old intact female Great dane aﬀorded the opportunity to
illustrate the acute CRP dynamics in a spontaneous case
from appearance of the ﬁrst local inﬂammatory signs and
after 24 h, when the fulminant clinical signs had developed.
Further, to illustrate the expected decline in CRP level after
cessation of an inﬂammatory stimulus, CRP concentrations
were measured in a clinical case of pyometra in a 5-year-old
intact American bulldog just before and 24 and 48 h after
ovariohysterectomy.
Serum was prepared by centrifugation (1500 · g, 5 min) of
blood samples after collection of the blood in plain vials with
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clot activator and separation gel (Vacuette, Greiner bio-one,
Austria). The serum samples were stored in plastic vials at
)80C until analysis for maximally 8 weeks.
CRP analysis
The analysis for canine CRP was performed with the Phase
Range canine CRP ELISA (Tridelta Development Ltd,
Kildare, UK).
Assay characteristics
Serum samples from additionally 25 client-owned unclassiﬁed
dogs were also included to investigate the characteristics of the
ELISA assay. The intra-assay variation [coeﬃcient of vari-
ation (CV)] was determined from the diﬀerence between
duplicate determinations of CRP concentration in 63 canine
serum samples. Twenty-nine of these samples were run in
duplicate in another run to assess the inter-assay variation.
Additionally, the inter-assay CV was determined from the
mean value and the standard deviation of six to eight replicate
determinations of two serum pools with diﬀerent CRP
concentrations. The pools were frozen in aliquots and only
vials needed for each speciﬁc analytical run were thawed to
prevent potential variation as a result of repetitive freeze–thaw
cycles. Inaccuracy was evaluated indirectly by investigating
linearity under dilution of a canine serum pool with a high
CRP concentration with the sample diluent provided with the
assay (Jensen, 2000). The DL was calculated based on data
from 26 replicate determinations of the diluent buﬀer from the
assay (Bu¨ttner et al., 1980).
Statistical methods
Intra- and inter-assay variations (intra- and inter-assay CV)
and DL (P < 0.01) were calculated using routine descriptive
statistical procedures (Box et al., 1978; Bu¨ttner et al., 1980).
Lack-of-ﬁt tests were performed to investigate whether
straight-line regression models actually represented a straight
line appropriately (Weisberg, 1985). Investigation of linearity
under dilution was accomplished by regression analysis in
linear and logarithmic transformation. The latter was intro-
duced in order to achieve homogeneity of the variance
(Weisberg, 1985). Kruskal–Wallis one-way analysis was per-
formed to determine whether the samples in the diﬀerent
diagnostic groups belonged to diﬀerent distributions. If the
outcome was signiﬁcant (P < 0.05), a multiple comparison
test was performed to get a more detailed picture of the
deviation (Siegel and Castellan, 1988).
Results
Assay characteristics
The intra- and inter-assay variations are given in Table 1.
Analysis of dilutions of a canine serum pool having a high
concentration of CRP resulted in a linear regression equa-
tion the intercept of which did not diﬀer from zero, as
shown in Table 2. The lack-of-ﬁt test revealed that the
dilution curve was in fact linear [P (LOF) ¼ 0.99]. In the
corresponding logarithmic regression analysis non-parallelity
was indicated by a slope diﬀerent than 1, although the
deviation from parallelity was small (slope ¼ 0.93). The DL
was calculated as 0.41 lg/ml (mean value 0.26 lg/ml, SD
0.06 lg/ml), thus below the range for normal canine sera
observed in earlier studies (0.8–22.6 lg/ml (Otabe et al.,
1998), 2.4–30.0 lg/ml (Yamamoto et al., 1994b) and in this
study (1.1–6.3 lg/ml).
Clinical assessment and CRP dynamics
The clinical characteristics and CRP concentration of the 46
dogs are given in Table 3. The Kruskal–Wallis analysis
revealed that the CRP level in the diﬀerent groups deviated
signiﬁcantly from each other (P < 0.0001). The multiple
comparison analysis showed that the serum CRP level in dogs
with infection was signiﬁcantly higher than in dogs from every
single other group in the study (P < 0.01). No other pair of
groups deviated signiﬁcantly from each other (P > 0.05). The
dynamics of the CRP level during development and after
cessation of spontaneously occurring inﬂammatory stimuli in
two dogs are illustrated in Fig. 1.
Discussion
Several studies show that serum CRP concentration is an
acute phase marker in the dog (Conner et al., 1988;
Yamamoto et al., 1992; Burton et al., 1994; Yamashita
et al., 1994; Hayashi et al., 2001). The rise in CRP is rapid
after various septic and aseptic inﬂammatory stimuli and
seemingly correlates to the extent and severity of the
inﬂammatory process (Yamamoto et al., 1994a; Otabe
et al., 2000). CRP might therefore be a useful diagnostic,
monitoring and prognostic parameter in the dog. The
freezing and storage of the serum samples prior to analysis
Table 1. Intra- and inter-assay variations of determinations of C-re-
active protein (CRP) in canine serum samples
No. of
samples
Mean
value (lg/ml)
SD
(lg/ml)
CV
(%)
Intra-assay 39 1.6 0.11a 6.9
24 44.4 4.49a 10.1
Inter-assay 15 2.3 0.60a 26.2
14 54.9 15.91a 29.0
Inter-assay 6 1.2 0.09b 7.5
8 92.3 20.45b 22.2
SD, standard deviation; CV, coeﬃcient of variation.
aBased on duplicate determinations of diﬀerent serum samples.
bBased on replicate determinations of the same serum-pool.
Table 2. Analytical inaccuracy of C-reactive protein (CRP) measure-
ments assessed by dilution of a canine serum pool with high CRP
content
Regression
y-
Intercept
y-Intercept
95% CI Slope
Slope
95% CI
P
(LOF) r
Linear 4.54 [)6.90; 15.97] 0.97 [0.89; 1.01] 0.99 0.99
Logarithmic 0.16 [0.05; 0.27] 0.93 [0.88; 0.98] 0.99 0.99
95% CI, 95% conﬁdence interval; P (LOF), probability for model
ﬁtting, i.e. that the data follow a straight line; r, coeﬃcient of corre-
lation.
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could be argued to cause pre-analytical variation, but the
eﬀect should be negligible in the present study, as canine
CRP was reported to be stable at )10C for at least 3 months
(Riley and Zontine, 1972).
The CRP ELISA used in this study measured CRP in a
linear and nearly proportional manner with intra- and
inter-assay CVs in the range of 6.9–10.1 and 7.5–29.0%,
respectively. For comparison, an ELISA employing phospho-
rylcholine binding of CRP revealed an intra- and inter-assay
CV of 12.5 and 22%, respectively (Eckersall et al., 1989).
Imprecision at the level found between runs in the present
study is usually considered unacceptable for diagnostic
purposes and reducing measures should be taken (Fraser,
1981). However, the increase of CRP in dogs in relation to
acute inﬂammation is of a magnitude (Caspi et al., 1987;
Conner et al., 1988; Otabe et al., 2000; Hayashi et al., 2001)
Table 3. Clinical characteristics of 46 dogs on which serum C-reactive protein concentration was measured
Clinical condition Breed Sex Age (years) CRP (lg/ml)
Clinically healthy
Beagle Male 6 6.3
Beagle Male 5 2.0
Beagle Male 2 1.5
Beagle Male 2 1.2
Beagle Female 6 2.0
Beagle Female 4 2.3
Beagle Female 3 1.1
Beagle Female 3 2.3
Range (median) 2–6 (3.5) 1.1–6.3 (2.0)
Neoplastic disease
Myxosarcoma Cocker spaniel Female 8 1.5
Mammary adenocarcinoma German shorthair Female 10 5.4
Mammary adenocarcinoma Mixed breed Female 6 0.8
Mammary adenocarcinoma German sheepdog Female 11 3.2
Seminoma Fox terrier Male 13 1.0
Mastocytoma English setter Male 8 1.3
Mastocytoma Fox terrier Male 9 1.3
Lymphosarcoma Golden retreiver Male 7 14.2
Papilloma Rottweiler Female 9 1.5
Cutaneous lipoma Mixed breed Female 11 2.3
Cutaneous histiocytoma American bulldog Male 6 3.1
Range (median) 6–13 (9) 0.8–14.2 (1.5)
Infection
Septic mastitis Great dane Female 12 51.7
Septic arthritis Labrador Male 1 86.8
Septic endometritis Cairn terrier Female 9 53.5
Pyometra Rottweiler Female 10 49.2
Pyometra Icelandic sheepdog Female 14 88.6
Septic pneumonia Mixed breed Female 12 75.7
Systemic leishmaniosis French bulldog Male 6 54.9
Angiostrongylosis German sheepdog Female 6 39.3
Crenosomiasis Mixed breed Male 2 28.5
Crenosomiasis Tiberian terrier Male 3 13.6
Crenosomiasis Mixed breed Female 5 29.3
Range (median) 1–14 (6) 13.6–88.6 (51.7)
Endocrine/metabolic disorder
Diabetes mellitus Rottweiler Male 5 0.6
Hypothyroidism Labrador Female 5 1.8
Hypoadrenocorticism German sheepdog Male 3 0.5
Hyperadrenocorticism Bull terrier Male 10 0.8
Hyperadrenocorticism Cairn terrier Male 8 0.9
Hyperadrenocorticism Welsh terrier Female 11 5.2
Metabolic myopathy English springer spaniel Male 2 0.8
Ovarial dysfunction Bichon friche´ Female 7 3.1
Range (median) 2–10 (5) 0.5–5.2 (0.8)
Miscellaneous
Disc prolapse Dalmatian Male 6 0.6
Urolithiasis Cairn terrier Male 7 1.1
Urolithiasis Fox terrier Male 7 2.9
Vasovagal dysfunction Boxer Female 4 1.1
Heart insuﬃciency Mixed breed Female 3 2.0
Inguinal hernia Pekingese Female 1 2.7
Chronic hyperplastic enteropathy Labrador Male 2 0.7
Chronic hyperplastic enteropathy Jack Russell terrier Male 1 1.3
Range (median) 1–7 (3.5) 0.6–2.9 (1.2)
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that would appear to diminish the consequences of a high CV.
This was further sustained, as the assay was able to detect the
expected dynamic changes during a spontaneous development
of an inﬂammatory response and after the cessation of an
inﬂammatory stimulus in two cases of acute mastitis and
pyometra, respectively (Fig. 1).
The CRP level in dogs with infection was higher than in
clinically healthy dogs and dogs with various other diseases
(Table 3). This is in accordance to former studies on CRP and
conﬁrms that CRP could be a useful diagnostic parameter for
infection.
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Several researchers have identified serum C-reactive
protein (CRP) as a useful acute phase marker in the dog.
The normal physiologic concentration of CRP is low but
increases rapidly with the onset of acute inflammation or
tissue destruction, and changes in CRP during the
course of disease seem to reflect the underlying disease
activity.1-11 Several methods for measuring canine serum
and plasma CRP concentrations have been developed
for use in individual studies, including ELISA,6,12 slide
reversed passive latex agglutination,9 immunodiffu-
sion,4,6 electroimmunoassay,11 quantitative capillary
reversed passive latex agglutination,13 and immunotur-
bidometric assay.14 Recently, a commercially available
ELISA specific for canine CRP was validated.15 However,
to use CRP concentration for routine diagnosis and mon-
itoring, a rapid automated assay is needed. A turbido-
metric immunoassay (TIA) for measuring human CRP
concentration is available (Bayer CRP TIA, Bayer,
Newbury, UK). The principle of the analysis is the bind-
ing of CRP to polyclonal goat anti-human CRP antibod-
ies to form a precipitate that is measured turbidometri-
cally. In previous investigations of the cross-reactivity of
canine CRP with different polyclonal and monoclonal
anti-human CRP antibodies, either no cross-reactivi-
ty11,16-18 or insufficient cross-reactivity for assay purposes
has been recorded.6,19,20
The aim of this study was to evaluate the reliability
of the Bayer CRP TIA for measuring canine serum CRP
concentration. We investigated the cross-reactivity of
canine CRP with the anti-human CRP antibody, assay
characteristics (imprecision, inaccuracy, and detection
limit), and the ability of the assay to differentiate
between clinically healthy dogs and relevant groups of
diseased dogs.
Materials and Methods
CRP analysis
The Bayer CRP TIA (lot 0198X) designed for the determi-
nation of human serum CRP concentration was used for
the heterologous determination of CRP concentration in
canine serum samples. According to the manufacturer's
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C-Reactive Protein (CRP) Turbidometric Immunoassay
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Background: Serum C-reactive protein (CRP) is an acute phase marker in dogs that is useful for the diagnosis and monitoring of
inflammatory disease. Rapid, reliable, and automated assays are preferable for routine evaluation of canine serum CRP concen-
tration. Objective: The aim of this study was to evaluate whether canine serum CRP concentration could be measured reliably
using an automated turbidometric immunoassay (TIA) designed for use with human serum. Methods: A commercially available
TIA for human serum CRP (Bayer, Newbury, UK) was used to measure canine serum CRP concentration. Cross-reactivity of anti-
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and interassay imprecision ranged from 5.2% to 10.8% and 3.0% to 10.2%, respectively. Serum CRP concentration was measured
in a linear and proportional manner. There was no significant disagreement and there was linear correlation of the results in the
comparison of methodologies, except for a slight proportional discrepancy at low CRP concentrations (<10 µg/mL). Dogs with
infections had a significantly higher concentration of serum CRP than did all other dogs, and dogs with neoplasia had a signifi-
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measured reliably using the commercially available TIA designed for human CRP (Vet Clin Pathol. 2003;32:81-87).
©2003 American Society for Veterinary Clinical Pathology
Key Words: Acute phase marker, C-reactive protein, dog, immunoassay, test validation
From the Central Laboratory (Kjelgaard-Hansen, Jensen) and the Small Animal Hospital (Kristensen), Department of Clinical Studies, The Royal
Veterinary and Agricultural University, DK-1870 Frederiksberg, Denmark. Corresponding author: Mads Kjelgaard-Hansen, Central Laboratory,
Department of Clinical Studies, Royal Veterinary and Agricultural University, 3 Gronnegaardsvej, DK-1870 Frederiksberg, Denmark (mjkh@kvl.dk).
©2003 American Society for Veterinary Clinical Pathology
———◆———
recommendations, the analysis was performed using an
automated analyzer (ADVIA 1650 Chemistry System,
Bayer); a human CRP calibrator (lot 0226X, Bayer) was
used to create the calibration curve. For samples used for
method comparison, the concentration of CRP was
determined simultaneously using a commercially avail-
able ELISA specific for canine CRP (canine CRP ELISA,
Tridelta Development Ltd, Kildare, UK) that had been
validated previously.15
Cross-reactivity of antigen
Investigation of cross-reactivity between canine CRP
and the goat anti-human CRP antibody (Bayer) was per-
formed using an Ouchterlony procedure21 in a 1% (w/v)
agarose gel (Agarose Litex, Bie & Berntsen, Rodovre,
Denmark) prepared in phosphate-buffered saline (0.01
M, pH 7.7, Bie & Berntsen). The goat anti-human CRP
antibody was placed in the center well, and human CRP
calibrator (Bayer) and canine serum samples were
placed in evenly distributed adjacent wells. Canine sera
included 2 canine serum samples with high CRP con-
centrations (61.0 µg/mL and 89.9 µg/mL) and a canine
serum pool with a high CRP concentration (102.6 µg/mL)
as determined by ELISA (Tridelta Development Ltd).The
gel was scored after 24 hours of incubation in a humid
chamber at room temperature (~25°C).
Assay characteristics of the TIA
The intra-assay variation between replicates was deter-
mined as the coefficient of variation (CV) from a pooled
variance estimate of the difference between duplicate
determinations at low (<20 µg/mL) and high (>20 µg/mL)
CRP concentrations from 39 and 40 observations, respec-
tively.The interassay CV was determined from the mean
and SD of 7 replicate determinations of 2 serum pools
with different CRP concentrations. The pools were
frozen in aliquots, and only vials needed for each analyt-
ical run were thawed to prevent potential variation due
to repetitive freeze-thaw cycles. Inaccuracy was investi-
gated by method comparison and evaluation of linearity
under dilution.22 For the study of linearity under dilution,
duplicate determinations of CRP concentration were
made on dilutions of a serum pool with a high concen-
tration of CRP diluted 0%, 10%, 20%, 40%, 50%, 60%, 90%,
95%, and 100% using physiologic saline (0.9% NaCl).The
detection limit (DL) was calculated based on data from
12 replicate determinations of physiologic saline.23
Samples
Fifty-six dogs were included in the study. Forty-eight
dogs were presented by their owners to the Small
Animal Veterinary Teaching Hospital (Royal Veterinary
and Agricultural University, Denmark) for various diag-
nostic, therapeutic, or prophylactic procedures between
December 2001 and May 2002. Eight dogs were clinical-
ly healthy Beagles from a research colony. All dogs
underwent clinical examination, and the results of stan-
dard hematological and clinical chemical profiles were
evaluated at our laboratory.24 Additional diagnostic tests
for each dog were conducted at the discretion of the
individual clinician (eg, endocrine testing, biopsies,
radiography, evaluation of blood smears, or microbial
testing).
Based on the results of the above examinations and
the final clinical diagnosis, the 56 dogs were retrospec-
tively assigned to 5 groups: clinically healthy dogs
(n=14), dogs with neoplasia (n=11), dogs with infections
(n=13), dogs with endocrine/metabolic disorders (n=8),
and dogs with miscellaneous diseases not belonging to
any of the former groups (n=10). Clinically healthy dogs
had unremarkable findings on physical and clinical
pathologic examinations. Dogs with neoplasia had
tumors that were cytologically and/or histologically
characterized as neoplastic (benign and malignant).
Dogs with infections had a pathogen identified that
could be related to the pathologic findings. Dogs with
endocrine/metabolic disorders had a final diagnosis
that could be related to a hormonal or metabolic mal-
function or disorder. Dogs with miscellaneous diseases
had various diagnoses and no clinical findings to associ-
ate them with any of the other groups.
Seventy-nine serum samples, selected from sam-
ples submitted to our laboratory between December
2001 and May 2002 from dogs presented to our hospital,
were used to investigate the assay characteristics of the
TIA method and for method comparison. Nineteen of
these samples were from dogs noted above and the
remainder from unclassified dogs. The selections were
made at random from samples with low (<20 µg/mL)
and high (>20 µg/mL) CRP concentrations (n=39 and
n= 40, respectively) as determined by ELISA (Tridelta
Development Ltd). In all cases, serum was prepared by
centrifugation (2000g, 5 minutes) of blood samples after
collection in plain vials with clot activator and separa-
tion gel (Vacuette, Greiner Bio-One, Kremsmuenster,
Austria). The serum samples were stored in plastic vials
at –80°C until analysis, for a maximum of 6 months.
Statistical analysis
Arithmetic means, medians, intra- and interassay CVs ,
and DL (P < .01) were calculated using routine descrip-
tive statistical procedures.23,25 Investigation of linearity
under dilution was accomplished by ordinary least-
squares linear regression analysis with linear and loga-
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rithmic transformations. Logarithmic transformations
were performed to achieve homogeneity of the vari-
ance.26 Methods were compared with the Wilcoxon
signed rank test to determine whether paired values
from both methods were significantly different,27 with
an Altman-Bland plot to reveal any possible discrepan-
cy,22 and with Passing-Bablok regression analysis to
derive regression data.28 The Runs test was performed in
all types of regression analyses to determine whether
data deviated significantly from the applied model.29
Comparison between diagnostic groups was made
using the Kruskal-Wallis test; when significant results
were obtained, Dunn’s multiple comparison test was
applied to get a more detailed picture of the deviation.29
Significance was set at P < .05 unless otherwise stated.
Results
Cross-reactivity of antigens
The result of the Ouchterlony procedure indicated that
the polyclonal goat anti-human CRP antibodies used in
the TIA were able to precipitate with canine sera and
serum pool with high CRP concentrations (Figure 1). A
reaction of partial identity between the TIA human CRP
calibrator and the canine sera was observed, with spurs
formed, indicating that only a fraction of the polyclonal
anti-human CRP antibodies formed a precipitate with
canine acute phase sera, but also indicating that the pre-
cipitation with the canine sera was as specific to canine
CRP as it was to human CRP (assay calibrator; no reac-
tion of nonidentity was seen).Thus, the canine sera con-
tained antigenic determinants identical to human CRP
antigenic determinants, but no antigenic determinants
different from human CRP antigenic determinants that
precipitated with the polyclonal goat anti-human CRP
antibodies.
Assay characteristics
The intra- and interassay CVs ranged from 5.2% to
10.8% and 3.0% to 10.2%, respectively, with the highest
CVs in serum samples with low CRP concentrations
(Table 1).The investigation of inaccuracy by dilution of a
canine serum pool resulted in a linear regression equa-
tion in which x = the expected level according to dilution
of the serum pool and y = the measured level and in
which the intercept and slope did not differ from 0 and
1, respectively (Table 2). The Runs test revealed that the
data did not deviate significantly from the linear model
(P = .07). In the corresponding logarithmic regression
analysis, the slope was not different from 1, thereby
indicating parallelism, and the logarithmic model also
showed linearity (Runs, P = .11). Hence, the TIA method
measured canine serum CRP concentration in a linear
and proportional manner. The detection limit was 0.07
µg/mL (mean 0.02 µg/mL, SD 0.02 µg/mL), which was
below the range for normal canine serum CRP concen-
tration observed in previous studies using other meth-
ods (0.8-22.6 µg/mL,30 2.4-30.0 µg/mL,9 and 1.1-6.3
µg/mL15) and in this study (0.5-8.4 µg/mL).
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Figure 1. Ouchterlony procedure for visualization of cross-reactiv-
ity between polyclonal goat anti-human C-reactive protein (CRP)
antibodies and canine sera. (A and D) Canine sera with high CRP
concentrations (A, 89.9 µg/mL; D, 61.0 µg/mL). (B) Canine serum
pool with a high CRP concentration (102.6 µg/mL). (C) Human CRP
(TIA calibrator 1005 µg/mL). (1) Polyclonal goat anti-human CRP
antibody (TIA reagent).
A
D 1 B
C
Table 1. Intra- and interassay variation in determinations of C-
reactive protein (CRP) concentration in canine serum samples.
Comparison No. CRP Concentration (µg/mL) CV* (%)
Samples Mean SD
Intra-assay† 39 4.0 0.43 10.8
40 67.0 3.48 5.2
Interassay‡ 7 3.8 0.39 10.2
7 101.6 3.05 3.0
*CV indicates coefficient of variation.
†Based on duplicate determinations of different serum samples.
‡Based on replicate determinations of the same serum pool.
Table 2. Analytical inaccuracy of C-reactive protein (CRP) concen-
trations assessed by dilution of a canine serum pool with a high
CRP concentration.
Value Regression
Linear Logarithmic
y-intercept (95% CI*) 6.29 (–3.35, 15.92) 0.18 (0.04, 0.32)
Slope (95% CI) 1.02 (0.90, 1.14) 0.93 (0.86, 1.02)
P (Runs)† .07 .11
r‡ .99 1.00
*CI indicates confidence interval.
†Probability for model fitting, ie, that the data follow a straight line (Runs test).
‡Coefficient of correlation.
Method comparison
Results of the Wilcoxon signed rank test indicated that
results from the 2 methods were not significantly differ-
ent (P = .83), the data did not deviate significantly from
the linear regression model (Runs, P = .22), and the slope
was not different from 1 (Figure 2 and Table 3). However,
the y-intercept differed from 0 (–2.16 µg/mL), and the
Altman-Bland plot indicated that a proportional discrep-
ancy at low CRP concentrations (<10 µg/mL) might be
present, although the deviations were small (Figure 3).
Comparison of serum CRP concentra-
tions in healthy 
and diseased dogs
The medians (ranges) of CRP con-
centrations in the 5 groups of dogs
were: clinically healthy dogs, 0.9
(0.5-8.4) µg/mL; dogs with neopla-
sia, 5.0 (1.1-91.9) µg/mL; dogs with
infections, 60.4 (33.3-88.8) µg/mL;
dogs with endocrine/metabolic dis-
eases, 2.4 (0.1-26.9) µg/mL; and dogs
with miscellaneous diseases, 3.9
(0.6-13.9) (Figure 4). The results of
the Kruskal-Wallis analysis indicat-
ed that the medians of the different
groups were significantly different
(P < .0001).The multiple comparison
test showed that median serum
CRP concentration in dogs with in-
fections was significantly higher
than that in any other group
(P < .001). Dogs with neoplasia had a
significantly higher median CRP
concentration than did clinically
healthy dogs (P < .01). Median CRP
TIA for Human CRP Applied to Canine CRP
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Figure 2. Passing-Bablok regression analysis for C-reactive pro-
tein (CRP) concentrations in canine serum samples using an ELISA
specific for canine CRP (ELISA CRP) and a turbidometric immuno-
assay (TIA CRP) designed for measuring human CRP concentration
(n = 38). The solid line represents the regression equation: TIA CRP
(µg/mL) = 1.06ELISA CRP (µg/mL)-2.16.
Table 3. Regression data for comparison of ELISA and turbidomet-
ric immunoassay (TIA) for evaluation of C-reactive protein concen-
trations.
Value ELISA vs TIA
n 38
y-intercept (95% CI*) –2.16 (–3.73, –1.11)
Slope (95% CI) 1.06 (0.97, 1.22)
P (Runs)† .22
P (W) ‡ .83
*CI indicates confidence interval.
†Probability for model fitting, ie, that the data follow a straight line (Runs test).
‡Probability for Wilcoxon signed rank test, ie, whether the paired values
from both methods are significantly different.
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Figure 3. Altmann-Bland difference plot for C-reactive protein (CRP) concentrations in
canine serum samples using an ELISA specific for canine CRP and a turbidometric
immunoassay (TIA) designed for measuring human CRP concentration (n = 38). Lines indi-
cate mean difference and ±1.96 SD of the mean difference.
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14.8
–1.96 SD
– 62.7
concentration was not significantly different (P < .05) in
any other pair of groups.
Discussion
Several researchers have shown that serum CRP con-
centration is a useful acute phase marker for routine
diagnostic purposes in dogs.1-11 However, none of the
previous methods available for measuring canine serum
CRP concentration was ideal for providing clinically
useful information in a routine diagnostic setting, where
a rapid, reliable, and automated method would be
preferable. The reliability of the rapid automated Bayer
CRP TIA evaluated in this study was found to be accept-
able for determination of CRP in canine serum.
The Bayer CRP TIA measured heterologous canine
serum CRP concentration with intra- and interassay
CVs in the ranges of 5.2-10.8% and 3.0-10.2%, respec-
tively.This level of intra- and interassay imprecision was
comparable to that of a commercially available ELISA
specific for canine CRP,15 although with the ELISA
imprecision increased with increasing CRP concentra-
tions, whereas the opposite trend was observed for the
TIA.The regression analysis of method comparison was
not biased because of these differences in imprecision,
because Passing-Bablok regression is insensitive to dif-
ferences in imprecision.31 The level of imprecision was
within the limits of the objective analytical performance
standard for imprecision (CVmax=12.2%) derived from
data on biological variation of canine CRP concentra-
tion.32
Canine serum CRP concentration was measured in
a linear and proportional manner by the Bayer TIA.
Comparison of methodologies showed no significant
differences in results and indicated a linear correlation
of the results of the canine-specific ELISA and the TIA.
However, a small proportional discrepancy was appar-
ent at low CRP concentrations (<10 µg/mL). The origin
of this discrepancy was not determined in the present
study, and further clarification may require access to
canine CRP standards. The median serum CRP concen-
tration in dogs with infections was, as expected, higher
compared to that of clinically healthy dogs and dogs
with various other diseases.This finding is in agreement
with those from other studies on canine serum CRP
concentration. The group of dogs with neoplasia had a
significantly higher median concentration of CRP than
did the clinically healthy dogs, as has been shown for
canine acute phase proteins33,34 and human CRP con-
centrations in similar comparisons.35,36
The possibility that the stability of CRP was com-
promised during freezing is unlikely, because canine
CRP has been reported to be stable at –10°C for at least
4 months.37 The Ouchterlony procedure revealed that
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Figure 4. Serum C-reactive protein (CRP) concentrations in 5 groups of dogs, measured using the Bayer CRP TIA, a turbidometric
immunoassay designed for determination of human serum CRP concentration.
the canine sera and serum pool with high CRP levels
contained a heterologous cross-reacting antigen, and
that none of the cross-reacting antigens differed from
those in the TIA calibrator. This finding strongly indi-
cates that the agreement in the results of the 2 tech-
niques was not due to nonspecific reactions, but rather
that the TIA most likely measured canine serum CRP
concentration specifically. In several investigations of
cross-reactivity between canine CRP and anti-human
CRP antibodies, either no cross-reactivity has been
observed11,16-18 or cross-reactivity was insufficient for
assay purposes.6,19,20 To our knowledge, this is the first
study to show enough cross-reactivity between canine
CRP and anti-human CRP antibodies to be meaningful
for assay purposes.
The results of the present study indicate that canine
serum CRP concentration can be measured reliably
using the Bayer CRP TIA, which is designed for measur-
ing human serum CRP concentration. Because this
assay method is automated and rapid, it is appropriate
for routine use in diagnostic laboratories. 
TIA for Human CRP Applied to Canine CRP
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Internal quality control of a turbidimetric
immunoassay for canine serum C-reactive protein
based on pooled patient samples
Mads Kjelgaard-Hansen, Asger Lundorff Jensen, Annemarie T. Kristensen
Background: Optimized internal quality control (IQC) procedures are important to ensure that only results without medically
important errors are used for medical decision-making and to ensure that unnecessary rejection of valid analytical runs is avoided.
Additionally, estimates of the analytical performance can be derived from IQC data. In the absence of available species-specific
standards of a compound, the use of alternative control materials based on patient samples is a possibility, although investigations
on the suitability of this approach are needed. Objectives: The objective of the study was to plan and implement a simple IQC
procedure with control material based on pooled canine serum samples for a turbidimetric immunoassay (TIA) for the
determination of human C-reactive protein (CRP) that recently was validated for the determination of canine serum CRP, and to
assess the clinical analytical performance of the assay. Methods: Proposed guidelines for the planning and implementation of IQC
procedures were followed by using 2 control materials. Quality requirements of the assay were defined objectively by means of
available data on biological variation, and goals for IQC performance were defined according to recommendations (probability of
error detection [Ped] . .90 and of false rejection [Pfr] , .05). Analytical performance was evaluated by means of medical decision
charts. Results: The control rule of 12.5s (ie, rejection of the analytical run if at least 1 of 2 controlmaterials deviates from themean by
more than 2.5 SD) fulfilled the criteria of predicted IQC performance (Ped5 .94–1.00, Pfr5 .03). The IQCmethod was successfully
implemented over a 14-week period. The observed coefficient of variation in the period of monitoring was 3.8% (low) and 2.9%
(high), which equals excellent analytical performance. Conclusions: It was possible to plan and implement a simple IQC procedure
for theCRP-TIAwith controlmaterials based on canine serum samples that fulfilled the criteria of high error detection and low false
rejection of valid analytical runs. The assay showed excellent long-term analytical performance over a 14-week period. (Vet Clin
Pathol. 2004;33:139–144)
2004 American Society for Veterinary Clinical Pathology
Key Words: Analytical performance, control material, C-reactive protein, dog, immunoassay, quality control
u
Internal quality control (IQC) is an important task
within the discipline of clinical chemistry. The reason to
apply proper IQC is primarily to ensure that results
used for medical purposes are reported only without
medically important errors (ie, errors that could
possibly alter the clinical decision). Another aspect of
proper IQC is to minimize the frequency or risk of
falsely rejecting valid analytical runs to minimize
unnecessary costs and waste in the laboratory.
Several guidelines have been proposed for the
implementation and optimization of statistical IQC,1,2
which describe steps of defining quality requirements
and setting up appropriate IQC procedures to optimize
detection of medically important errors and reduce the
risk of false rejection.
IQC usually is based on control materials traceable
to a certified reference material, when available (eg, the
International Federation of Clinical Chemistry and
Laboratory Medicine reference material #470 for human
serum components).3 Such standards and traceable
control materials are not yet available for canine acute
phase proteins (eg, canine serum C-reactive protein
[CRP]), although the problem is recognized and work
has been initiated.4 Thus, it could be of interest to
investigate the implemention of an IQC procedure for
canine CRP based on pooled patient samples as an
alternative control material.
Recently, an automated commercially available
human CRP turbidimetric immunoassay (CRP-TIA;
Bayer, Newbury, UK) was validated for the determina-
From the Central Laboratory (Kjelgaard-Hansen, Jensen) and the Small Animal Veterinary Teaching Hospital (Kristensen), Department of Small Animal Clinical
Sciences, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark. Corresponding author: Mads Kjelgaard-Hansen, Central Laboratory,
Department of Small Animal Clinical Sciences, The Royal Veterinary and Agricultural University, 3 Gronnegaardsvej, DK-1870 Frederiksberg, Denmark
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tion of canine serum CRP concentration.5 The scope of
the present study was to plan and implement an IQC
procedure for the CRP-TIA according to existing
guidelines1,2 by using control material based on pooled
patient samples. In addition, we estimated the long-
term analytical performance of the assay under the
control of the implemented IQC procedure.
Materials and methods
Assay
The Bayer CRP-TIA designed for the determination of
human serum CRP was used for the heterologous
determination of CRP in canine serum samples for
which it was previously validated.5 The principle of the
analysis is the binding of canine CRP to polyclonal goat
antihuman CRP antibodies to form a precipitate that is
measured turbidimetrically. Human CRP calibrator
(Bayer) was used to create a standard curve, and the
analysis was performed with an automated analyzer
(ADVIA 1650 chemistry system, Bayer) according to the
manufacturer’s description.
Control material
Serum samples originated from 15 client-owned dogs
presented to the Small Animal Veterinary Teaching
Hospital, Department of Small Animal Clinical Scien-
ces, The Royal Veterinary and Agricultural University,
Frederiksberg, Denmark, for various diagnostic, thera-
peutic or prophylactic measures. Serum was prepared
by centrifugation (2000g, 5 minutes) within 1 hour after
collection of the blood in plain vials with clot activator
and separation gel (Vacuette, Greiner Bio-One, Krems-
muenster, Austria). Two serum pools with different
concentrations of CRP (approximately 20 mg/L [low]
and 65 mg/L [high], as determined by the CRP-TIA)
were created by mixing a number (n) of individual
serum samples with low and high CRP concentrations
as determined by the CRP-TIA (range 15–35 mg/L [n5
6] for the low pool and 50–95 mg/L [n 5 9] for the high
pool). The pools were aliquoted and stored for
a maximum of 4 months in plastic vials at808C before
analysis.
Planning the IQC
The IQC procedure was planned as outlined by
proposed guidelines (Table 1).1,2
Define quality requirements for the test. The predefined
quality requirements to perform optimal IQC planning
were set equal to previously derived objective analytical
performance standards from a study on biological
variation of canine serum CRP (maximum allowable
bias5 9.5% and maximum allowable total error [TEmax]
5 29.6%).6
Determine method imprecision and bias. Method
imprecision was assessed in a small pilot study
consisting of 5 separate analytical runs of the pools
(data not shown); imprecision was approximately 4% at
the 2 control levels. The true bias of the assay could not
be assessed because of the lack of available external
standards. Because the previous study showed no
significant bias,5 the assay was assumed to have
acceptable bias (,9.5%). To assess the sensitivity of
the IQC procedure to changes in bias, both extremes of
acceptable observed bias (0.0% and 9.5%) were used in
the following steps.
Identify candidate IQC procedures. The list of candi-
date IQC procedures included 4 single rules with
constant limits, ie, the rule is violated if one of the
controls deviates more than a given number (x) of SDs
from the mean of the control material (1(x)s, 12s, 12.5s, 13s,
and 13.5s), and 1 multirule procedure (13s/22s), ie, either
of the control materials deviate more than 3 SDs or both
materials deviate more than 2 SDs from the mean within
the same analytical run.
Select goals for IQC performance. The goals for IQC
performance were set to a probability for detection of
medically important systematic error (Ped) of .90 or
higher and a probability of false rejection of a valid
analytical run (Pfr) of .05 or lower.
Select an appropriate IQC procedure. The predicted
performance of the candidate IQC procedures was
estimated by means of the commercially available
software package Validator 2.0 (Westgard Quality
Corporation, Ogunquit, ME, USA). The critical system-
atic error (ie, the systematic shift that would cause a 5%
risk of reporting a medically incorrect test result ([total
allowable error observed bias]/observed imprecision
1.65) was calculated,2 which in the present study gave
5.75s and 3.38s for observed bias of 0.0% and 9.5%,
respectively. The predicted performance was then
estimated with power functions for the candidate IQC
procedures, described in detail elsewhere,1 and ex-
pressed as Ped and Pfr for the detection of medically
important systematic errors. The simplest IQC pro-
cedure to fulfill the selected goals for IQC performance
was selected for implementation.
Table 1. Proposed steps for planning internal quality control (IQC).
1. Define quality requirements for the test
2. Determine method imprecision and bias
3. Identify candidate IQC procedures
4. Select goals for IQC performance
5. Select an appropriate IQC procedure
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Implementation of IQC
The selected IQC procedure was implemented and
performed twice weekly from January 24 to May 8,
2003, by thawing and analyzing a new vial of control
material at each control point. Violation of the IQC
rule was monitored by QCTool (Westgard Quality
Corporation), available online.7 If the control rule
was violated, error detection was performed and
new controls were run immediately after correction
of the error.
Evaluation of analytical performance
A method evaluation decision chart (MEDx)8 was used
to assess the analytical performance of the CRP-TIA
during stable analytical performance. The MEDx
method uses the objective analytical performance
standard for TEmax derived from data on biological
variation to rank the performance as poor, marginal,
good, or excellent according to defined criteria.8 The
observed imprecision of the CRP-TIA (expressed as the
coefficient of variation of the non-rejected measure-
ments of the control material) was plotted against the
full range of acceptable bias (0.0–9.5%) to assess the
performance.
Results
The control rule of 12.5s was the simplest rule to fulfill
the criteria of predicted IQC performance (Ped 5 .94–
1.00, Pfr 5 .03) within the range of acceptable bias (0.0–
9.5%). All candidate procedures except 12s (Ped 5 1.00,
Pfr 5 .09) fulfilled the criteria at minimum bias (Figure
1A), but only 12.5s and 13s/22s fulfilled the criteria at the
maximum allowable bias (Figure 1B). The 13s and 13.5s
rules had a Ped that was too low, and 12s had a Pfr value
that was too high. Thirty control measurements of each
control material were performed during the period of
monitoring (Figure 2), and all analytical runs were in
control except for 2 that exceeded the 12.5s criteria (run 9
[low] and run 28 [high]), thus indicating a medically
important error. In both instances, troubleshooting
detected a lamp error as the cause, and an acceptable
control run was obtained immediately after correction
of the lamp error. The observed analytical imprecisions
of the assay during stable analytical performance were
3.8% (low) and 2.9% (high), not exceeding the 4% used
during IQC development.
Evaluation of the CRP-TIA by MEDx chart showed
that the observed imprecision at both levels of CRP
corresponded to excellent analytical performance with-
in the range of acceptable bias (Figure 3).
Discussion
Planning and implementation of IQC in clinical chem-
istry laboratories is important to ensure that results with
medically important errors are not reported and used for
diagnostic purposes and to ensure that the risk of
rejecting valid analytical runs is minimized to avoid
unnecessary waste of time and material. In the absence
of available standards for canine serum CRP, we
planned and implemented an acceptable IQC procedure
for the CRP-TIA based on pooled patient serum samples
as an alternative control material.
The results showed that it was possible to plan and
implement an IQC procedure. The procedure (12.5s)
fulfilled the criteria of predicted high error detection of
medically important systematic errors (Ped 5 .94–1.00)
and low false rejection (Pfr 5 .03) of valid analytical
runs. It was interesting to observe that the traditional
criterion of Levey-Jennings charts (12s) failed to fulfil the
Figure 1. Power functions for systematic error for 5 different control
rules of 2 control materials (N 5 2) within the same analytical run (R 5
1). Four single rules (12s, 12.5s, 13s, and 13.5s) with constant limits (ie, the
rule is violated if one of the controls deviates more than a given number
[x] of SDs from the mean observation of the control material [1(x)s]) and 1
multirule procedure (13s/22s) (ie, either of the control materials deviate
more than 3 SDs or both materials deviate more than 2 SDs from the
mean observation within the same analytical run) were included.
Probabilities of error detection (Ped) and of false rejection (Pfr) for the
critical systematic error (SEcrit) are shown in the boxes at the right. The
SEcrit5 5.75 (A) and 3.38 (B) corresponding to an observed bias of 0.0%
and 9.5%, respectively.
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criteria of predicted IQC performance (Ped 5 .99–1.00,
Pfr 5 .09) and would have resulted in 3 times as many
false rejections of valid analytical runs than the chosen
procedure, resulting in unnecessary waste of material
and time.
Previously published guidelines for planning and
implementation of IQC procedures1,2 were followed in
the planning stage. Data on biological variation were
used to define quality requirements of the test; this
application has been proposed as an objective way to
define analytical quality requirements,9,10 and has been
accepted as the best method to define the quality re-
quirements when a direct ‘‘evaluation of the effect
of analytical performance on clinical outcome in specific
clinical settings’’ is not available.11 To ensure the
applicability of the IQC with the number of available
control materials and to ease application, the list of
candidate IQC procedures was limited to include
procedures using only 2 control materials within a single
run. This approach may have lead to a rejection of all
candidate procedures; had that occurred, more complex
IQC procedures could have been added and tested. The
candidate IQC procedures were chosen primarily to
keep the procedure simple. The goals set for predicted
IQC performance (.90 and .05 for Ped and Pfr, re-
spectively) have been proposed as acceptable require-
ments,2 but stricter criteria were targeted. There often is
a trade-off between stricter IQC performance and the
wish for simple IQC procedures.
When performing IQCby including controlmaterial
tomonitor changes in analytical performance, the ICQ is,
in a strict sense, performed only at the point concen-
trations of the control materials. Therefore, it is impor-
tant to ensure that the levels of the compound in the
control materials are close to the level(s) of clinical
importance (ie, where the detection of clinically impor-
tant errors is essential). Traditionally, 1 control value is
selected close to or within the normal range of values for
healthy individuals, because this level is importantwhen
using a cut-off limit statistically derived from data on
healthy individuals. Another control value is then
selectedwithin the range of values found in pathological
conditions, to control the analytical performance at
abnormal levels. However, studies on changes in canine
CRP concentration in systemic inflammation,12–15 to-
Figure 2. Control charts for low (A) and high (B) pools used as control
materials for the CRP turbidimetric immunoassay (CRP-TIA) during 30
control runs over a 14-week period. Horizontal lines represent mean of
control material measurements and mean 6 the given number of SDs.
The IQC rule is violated if the lines representing mean 6 2.5 SDs are
exceeded.
Figure 3. Medical decision chart for assessing analytical performance of
the CRP turbidimetric immunoassay (CRP-TIA). Maximum allowable error
(TEmax 5 29.6%) is plotted on the y-axis and fractions (0.25, 0.33 and
0.5) of the TEmax are plotted on the x-axis as criteria for ranking analytical
performance. Observed operating ranges of low control (solid line) and
high control (dotted line) are plotted as observed imprecision (3.8% and
2.9%, respectively) versus the range of allowable bias of 0.0%–9.5%.
CRP-TIA performance was excellent at both levels of control material.
Internal Quality Control of a Canine CRP-TIA
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gether with a study on the biological variation of canine
CRP,6 indicate that the diagnostic sensitivity of CRP for
the detection of systemic inflammation most likely is
provided by a large relative change in concentration
rather thanby the use of a cut-off level close to the normal
range. The low index of individuality of canine CRP
makes the use of a traditional reference interval di-
agnostically insensitive at the level of individuals.6 On
the contrary, the diagnostic specificity of canine CRP can
be enhanced without seriously impairing diagnostic
sensitivity by using a cut-off limit somewhat above the
normal range. Optimally, this cut-off should be derived
fromCRP levels in groups of dogswith different diseases
of clinical interest. Preliminary results in our laboratory
suggest that a clinical decision limit for canine CRP
optimized todifferentiate amongunhealthydogswith or
without systemic inflammation is in the range of 16–18
mg/L for this assay (unpublished results). A 3rd control
within the normal range would have further opti-
mized the IQC procedure, to also detect errors at the
normal level and enhance detection of proportional
errors. However, fluctuation within the normal range
of CRP values has not yet been found to be clinically
useful in canine medicine as it has in human
medicine.16 Thus, the control levels used in the
present study were placed in the critical region of
a clinical decision limit (approximately 20 mg/L) and
at a pathologic level (65 mg/L) to ensure control of
clinically important errors during the establishment of
a diagnosis and during monitoring of inflammation
after the establishment of a diagnosis.
In contrast to the use of traceable standard material
that enables estimation of the absolute level of bias, the
use of patient samples as control material limits the
control of bias to a detection of a change in bias.
Participation in multilaboratory proficiency testing
programs also enables the assessment of bias
relative to other laboratories, but such programs are
yet to be established for canine CRP. However, because
significant bias in the CRP-TIA was proven unlikely by
other means,5 the monitoring of changes in systematic
error should be sufficient.
The observed imprecision at the 2 levels of CRP
corresponded to excellent analytical performance of the
CRP-TIA as evaluated by the MEDx chart, which is
a further validation of the assay for routine use in canine
medicine. Retrospective determination of assay impre-
cision using control materials has been argued to be
biased by selection; assessment is more correctly
performed by using a separate material for evaluation
of imprecision only.1 In the present study, error in the
assessment of imprecision because of selection was
considered minimal, since the values resembled earlier
observations made using separate material5.
The use of control material in IQC is based on an
assumption of a constant concentration of the com-
pound in the control material throughout the control
period; thus, it is important to ensure that the pools of
patient serum samples are stable.The period of use in
the present study was limited to 14 weeks because
a previous study showed canine CRP to be stable at
108C for at least 4 months.17 Continuous IQC based on
patient samples can then be performed by preparation
of pools of fresh material every 3 months. The pools can
be run concurrently with established control materials
for 6–8 control points to establish data for the new
control material during a period of stable analytical
performance under control of the established control
material. This procedure can be repeated every 3
months. In the present study, a trend of decrease was
present in the high pool after the 25th control point (12
weeks of storage); whether this represents a limit of
stability or another source of variation is unclear.
Further studies of the storage properties of canine
CRP at storage temperatures used in modern laborato-
ries are needed to elucidate this aspect and enable
optimization of a continuous IQC based on patient
samples. The guidelines used here for planning the IQC
procedure are applicable to many types of tests. The
results of the present study suggest that similar
procedures could be applied to other veterinary assays
and to species-specific IQC when commercial standards
are not available.
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Summary 
The determination of canine serum C-reactive protein (CRP) is reported to be of clinical 
value for diagnostic and monitoring purposes. Recently, an automated turbidimetric 
immunoassay (CRP-TIA) has been validated for the determination of canine serum 
CRP, which facilitates routine use of CRP in canine medicine. Method-specific clinical 
decision levels are necessary to enable the evaluation of single measurements of CRP. 
The objective of this study was to estimate the reference limits of canine serum CRP 
determined by the CRP-TIA of healthy dogs and to assess the optimal cut-off values for 
CRP to differentiate dogs with conditions causing systemic inflammation from (1) 
healthy dogs and (2) diseased dogs without systemic inflammation. Fifty-nine healthy 
dogs, 35 diseased dogs without systemic inflammation and 50 dogs in three different 
groups with conditions causing systemic inflammation (pyometra [10 dogs], 23h post 
operative stress [14 dogs] and Angiostrongylus vasorum infection [26 dogs]) were 
included in the study. The lower and upper reference limits for healthy dogs were 0.4 
mg/L and 15.9 mg/L, respectively. The optimal cut-off value to differentiate between 
dogs in setting (1) and (2) was within 11.1-14.8 mg/L and 16.0-17.8 mg/L, respectively 
when diagnostic specificity was favoured, seemingly without impairing the detection of 
a wide range of inflammatory activity. The results of the study can be used as a 
guideline for the evaluation of single measurements of canine CRP in different clinical 
settings.
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Introduction 
C-reactive protein (CRP) is a major acute phase protein in dogs characterized by a 
marked change in serum concentration consistent with systemic inflammatory activity 
(Conner et al., 1988; Yamamoto et al., 1994a; Hayashi et al., 2001). Several studies 
have reported canine serum CRP to be a fast, diagnostically sensitive and specific 
marker for systemic inflammatory activity very likely to be useful for routine diagnostic 
and monitoring purposes in canine medicine (Ndung'u et al., 1991; Otabe et al., 2000; 
Jergens et al., 2003; Martinez-Subiela et al., 2003a). Most studies on methodologies 
for canine CRP determination have been performed using locally developed non-
commercial assays for the determination of serum CRP concentration, but a few 
commercially available assays have been validated for canine serum CRP (an 
automated turbidimetric immunoassay [CRP-TIA, Bayer, Newbury, UK] (Kjelgaard-
Hansen et al., 2003a), a canine CRP-ELISA [Tridelta, Kildare, Ireland] (Kjelgaard-
Hansen et al., 2003b) and a semi-quantitative immunochromatographic assay [CRP 
rapid assay pack, EVL, Woerden, The Netherlands] (McGrotty et al., 2004)), which 
should enable wide-spread routine laboratory use. Studies on the biological variation of 
canine CRP have been performed, which amongst other things facilitate the clinical 
evaluation of serially obtained CRP measurements from the same individual (Martinez-
Subiela et al., 2003b; Kjelgaard-Hansen et al., 2003c). However, to also enable clinical 
decision-making based on single CRP measurements it is necessary to establish 
clinical decision levels such as reference limits for healthy dogs and cut-off values for 
specific clinical settings. The previously reported ranges of CRP in healthy dogs seem 
to partly depend on the method used as the range varies considerably between studies 
using different methods; 0.8-22.6 mg/L (Otabe et al., 1998), 2.4-30.0 mg/L (Yamamoto 
et al., 1994b), 0-67.4 mg/L (Börngen, 1998) and 1.2-6.4 mg/L (Kjelgaard-Hansen et al., 
2003b). This problem is partly due to the lack of recognized standards for canine CRP, 
as a common reference standard most likely would enable a decrease of this inter-
method variation. Until such standards are available it is necessary to establish 
method-specific clinical decision levels. 
The objective of this study was to estimate the reference limits of canine serum CRP 
determined by the CRP-TIA of healthy dogs and to assess the optimal cut-off values for 
CRP to differentiate dogs with conditions causing systemic inflammation from (1) 
healthy dogs and (2) diseased dogs without systemic inflammation. 
______________________________________________________________________ 
 
76 
 
Materials and methods 
Assay 
A CRP-TIA (Bayer, Newbury, UK) designed for the determination of human serum CRP 
was used for the heterologous determination of CRP in canine serum samples for 
which it has previously been validated (Kjelgaard-Hansen et al., 2003a). The principle 
of the analysis is the binding of canine CRP to polyclonal goat anti-human CRP 
antibodies to form a precipitate that is measured turbidimetrically. Human CRP 
calibrator (Bayer, Newbury, UK) was used to create a standard curve and the analysis 
was performed using an automated analyzer (ADVIA 1650 chemistry system, Bayer, 
Newbury, UK) according to the manufacturer's description. Routine canine CRP-
specific internal quality control, as previously described (Kjelgaard-Hansen et al., 
2004b) was also performed throughout the study period to ensure detection of possible 
clinically important errors. 
 
Samples 
When nothing else is stated the serum samples used were obtained from client-owned 
dogs presented at the Small Animal Veterinary Teaching Hospital, Department of Small 
Animal Clinical Studies, The Royal Veterinary and Agricultural University, Denmark for 
various diagnostic, therapeutic or prophylactic measures. Routine pre-anaesthetic 
serum samples from 59 dogs undergoing elective surgery (mainly ovariohysterectomi, 
orchidectomy or removal of persistent deciduous teeth) were included in the study to 
represent samples from healthy dogs. None of the dogs had clinical, haematological or 
biochemical abnormalities concordant with any disease activity. The healthy dogs were 
represented by 25 different breeds and 13 cross-breeds with an age-span of ½-12 
years (median 2 years).  
Thirty-five Cavalier King Charles Spaniels (age-span of 2½-13½ years [median 7 
years]) with untreated moderate to severe mitral regurgitation (a regurgitant jet 
occupying 50-100% of the left atrial area on echocardiography) were included to 
represent diseased dogs without systemic inflammation. The dogs were enrolled in 
connection with a mitral valve disease screening programme and a study on 
assessment of changes in haemostatic markers performed at the Department of 
Animal and Veterinary Basic Sciences, The Royal Veterinary and Agricultural 
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University, Denmark. None of these dogs had clinical or haematological signs of any 
systemic inflammatory process.  
Three different groups represented dogs with different conditions causing systemic 
inflammation. Ten dogs with pyometra, 26 dogs with Angiostrongylus vasorum 
infections (positive Baerman test) and 14 dogs sampled 23 hours after elective 
abdominal surgery (sampled to represent aseptic systemic inflammation (Conner et al., 
1988; Hayashi et al., 2001)). The 3 groups represented 6 breeds and 1 cross-breed, 
aged 1-13 years (median 6 years); at least 13 breeds, aged 1-11 years (median 3 
years) and 5 breeds, aged ½-10 years (median 4 years), respectively. No other source 
of systemic inflammation was detected clinically in these dogs. 
For all samples serum was prepared by centrifugation (2000g, 5 minutes) within 1 hour 
after collection of the blood in plain vials with clot activator and separation gel 
(Vacuette, Greiner bio-one, Austria). The CRP determination was performed 
immediately after serum preparation except for dogs with mitral regurgitation and 
aseptic inflammation, where serum was stored in plastic vials at -80˚C for a maximum 
of 18 and 6 months, respectively before analysis. 
 
Statistical methods 
The reference limits (outer 90% confidence limits of the central 95% confidence interval 
(CI)) of healthy dogs were established as previously outlined (Solberg, 1996); a 
goodness-of-fit test of the reference population to a Gaussian distribution was 
performed by means of the Kolmogorov-Smirnov test and a logarithmic transformation 
was performed in case of skewed data to obtain a distribution fit for the parametric 
approach. The mean and standard deviation (SD) was estimated and the lower and 
upper reference limit calculated as the mean-1.96SD-2.81SD/n½ and 
mean+1.96SD+2.81SD/n½, respectively. Transformation back to the ordinary scale was 
performed if transformed data were used. Receiver operating characteristic (ROC) 
analysis (Zweig and Campbell, 1993) was performed to assess the optimal cut-off 
values to differentiate dogs with conditions causing systemic inflammation from (1) 
healthy dogs and (2) diseased dogs without systemic inflammation. The cut-off value 
for CRP was obtained at sensitivity=1 and specificity=1 and at the maximum differential 
positive rate (maxDPR), i.e. where sensitivity-(1-specificity) was highest.  
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Results 
The CRP concentrations varied markedly between the different groups of dogs (Fig 1). 
The CRP concentrations in the group of healthy dogs were positively skewed and 
deviated significantly from a Gaussian distribution (P<0.001). No skewness or deviation 
from Gaussian distribution was observed after logarithmic transformation. The 
logarithmic reference limits were -0.38 mg/L and 1.20 mg/L (mean=0.41 mg/L, 
SD=0.34 mg/L and n=59), corresponding to 0.4 mg/L and 15.9 mg/L on the ordinary 
scale for the lower and upper limit, respectively. The optimal cut-off values for the 
different settings are summarized in Table 1 and 2. 
 
Discussion 
The reference limits for a diagnostic parameter is derived from data on sampled 
healthy individuals to assess what levels could be expected in non-diseased individuals 
(Solberg, 1996). In the case of canine CRP, only the upper reference limit of 15.9 mg/L 
is of current interest because any clinical significance of very low levels of CRP or 
fluctuations within normal levels has not been established in canine medicine. The 
outer 90% confidence limits of the traditional 95% confidence interval were used to 
account for the limited sample size (Solberg, 1996).   
The sub-groups of dogs with conditions causing systemic inflammation were analysed 
separately when performing the ROC analysis, as different causes are reported to 
result in markedly different distributions of inflammatory responses and CRP 
concentrations (Yamamoto et al., 1993; Higgins et al., 2003; Kjelgaard-Hansen et al., 
2004a). This was not done to resemble any clinical setting because canine CRP, as a 
major acute phase protein, is recognized as a diagnostic sensitive and specific marker 
of inflammatory activity in general, but non-specific to the cause thereof (Eckersall and 
Conner, 1988; Hayashi et al., 2001). The pooling of dogs belonging to very different 
distributions of CRP values could have influenced the assessment of cut-off values by 
the ROC analysis. Additionally, the separate analysis of the different groups of dogs 
with conditions causing systemic inflammation enabled assessing the consequence of 
the different distributions of CRP concentrations to the cut-off value estimates. 
However, the separate use of (1) healthy dogs and (2) dogs with a non-inflammatory 
condition as control dogs in the assessment of clinical performance was performed to 
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resemble different clinical settings. Situation (1) resembled the use of CRP 
measurements for screening purposes, whereas (2) resembled the typical clinical 
situation where abilities to identify dogs with inflammatory activity from a population of 
diseased dogs are wanted. The estimated cut-off values optimized for high diagnostic 
specificity and for maxDPR, respectively were within narrow ranges regardless of the 
clinical setting, an indication of stable estimates. Regarding the clinical decision level 
optimized for high diagnostic sensitivity it should be noted that a sensitivity of 1 could 
only be obtained with cut-off=0 mg/L when detecting systemic inflammatory activity in 
A. vasorum-diseased dogs. A rather even distribution of CRP concentrations from low-
normal to markedly increased were observed in this group (Fig 1), despite they all had 
active A. vasorum infection, which per se includes larval migration (Bolt et al., 1994). 
Some of the dogs with A. vasorum most likely did not have a significant acute phase 
response at all, as several other haematological and biochemical indicators of systemic 
inflammation were also within reference range (data not shown). 
In general, the optimal cut-off level depends on the relative importance of diagnostic 
sensitivity and specificity (Linnet, 1988). Therefore, considerations should be made of 
whether they are of equal importance or either of them should be favoured. If, for 
instance, the test is used to differentiate dogs with systemic inflammation from healthy 
dogs, i.e. as a screening tool for systemic inflammation, a low prevalence is often 
expected and therefore, diagnostic specificity should be favoured to avoid a high 
number of false-positives (Linnet, 1988) and ensure an acceptable predictive value of a 
positive result. Additionally, in the case of canine CRP it appears that the diagnostic 
sensitivity in detecting systemic inflammatory activity lies within the large relative 
change in concentration, rather than in using cut-off levels close to the normal range 
(Conner et al., 1988; Otabe et al., 2000; Hayashi et al., 2001; Kjelgaard-Hansen et al., 
2003c). The latter because of an observed low index of individuality (low ratio between 
intra- and inter-individual coefficients of variation) of canine CRP, which in general 
makes the use of a traditional reference range diagnostically insensitive in the 
detection of small but significant changes at the level of individuals (Harris, 1974; 
Kjelgaard-Hansen et al., 2003c). Furthermore, favouring diagnostic specificity that 
could ensure high predictive value of a positive result seemed not to adversely impair 
the continued detection of a wide range of inflammatory activity. Thus, the clinical 
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decision levels should be within 11.1-14.8 mg/L and 16.0-17.8 mg/L for screening and 
diagnostic purposes, respectively.  
In Table 1 and 2 the cut-off levels at sensitivity=1 and at the maximum differential 
positive rate are also provided, should other settings require optimal diagnostic 
sensitivity or equal importance of diagnostic sensitivity and specificity, respectively.  
The age-range and -distribution were similar in the groups used in this study and 
previous studies have shown no age or sex variation of the CRP level in healthy dogs 
(Kuribayashi et al., 2003) and only very young dogs (under 3 months) are reported to 
have a different CRP acute phase response compared to other age-groups (above 3 
months) (Hayashi et al., 2001). Dogs under 3 months of age seemed to have a weaker 
CRP acute phase response than dogs in other age groups (Hayashi et al., 2001), 
which may impair the diagnostic sensitivity of canine serum CRP in the detection of 
significant systemic inflammation in this age-group. Additionally, previous studies 
reported that the canine pregnancy induces a significant acute phase response with 
elevated levels of CRP during mid-gestation (Eckersall et al., 1993; Kuribayashi et al., 
2003) which will most likely alter the diagnostic specificity of the detection of systemic 
inflammation by means of CRP measurements in this group. Thus, the results of the 
present study should be applicable for all non-pregnant dogs above 3 months of age 
and specific studies are needed to establish separate clinical decision levels for the 
pregnant and very young dogs. 
The result of the present study should be used as guidelines for clinical decision levels 
for canine serum CRP determined by the CRP-TIA. 
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Figure 1. Serum concentration of C-reactive protein in different groups of dogs. 
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Table 1. Estimates of the clinical decision levels for canine C-reactive protein (mg/L) to 
differentiate between healthy dogs and dogs with conditions causing systemic 
inflammation obtained by receiver operating characteristic analysis 
Groups compared: 
Healthy vs. 
CDL based on 
maxDPR 
(Se;Sp) 
CDL when  
Sensitivity=1 
(Se;Sp) 
CDL when 
Specificity=1 
(Se;Sp) 
Pyometra 11.1 (1;1) 11.1 (1;1) 11.1 (1;1) 
Aseptic inflammation 9.8 (1;0.98) 9.8 (1;0.98) 14.8 (0.93;1) 
Angiostrongylus 
vasorum 
9.8 (0.46;0.98) 0 (1;0) 11.6 (0.42;1) 
CDL; Clinical decision level. maxDPR; Maximum differential positive rate, i.e. where sensitivity-
(1-specificity) is highest, the optimal clinical decision level if sensitivity and specificity are of 
equal importance. Se; Diagnostic sensitivity. Sp; Diagnsotic specificity. 
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Table 2. Estimates of the clinical decision levels for canine C-reactive protein (mg/L) to 
differentiate between diseased dogs without systemic inflammation and dogs with 
conditions causing systemic inflammation obtained by receiver operating characteristic 
analysis 
Groups compared: 
Diseased dogs without 
systemic inflammation vs. 
CDL based on 
maxDPR 
(Se;Sp) 
CDL when 
Sensitivity=1 
(Se;Sp) 
CDL when 
Specificity=1 
(Se;Sp) 
Pyometra 9.6 (1;0.97) 9.6 (1;0.97) 17.8 (0.90;1) 
Aseptic inflammation 8.8 (1;0.97) 8.8 (1;0.97) 16.7 (0.93;1) 
Angiostrongylus vasorum 5.8 (0.69;0.91) 0 (1;0) 16.0 (0.38;1) 
CDL; Clinical decision level. maxDPR; Maximum differential positive rate, i.e. where sensitivity-
(1-specificity) is highest, the optimal clinical decision level if sensitivity and specificity are of 
equal importance. Se; Diagnostic sensitivity. Sp; Diagnsotic specificity. 
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Abstract 
Canine C-reactive protein (CRP) measurements were performed during treatment of a 
case of canine type II immune-mediated polyarthritis (IMPA) with several periods of 
inflammatory relapses to possibly provide clinically useful information not obtainable by 
means of complete blood cell count or clinical evaluation. Canine CRP is a 
diagnostically sensitive and specific marker of systemic inflammatory activity, but non-
specific regarding the stimulus thereof. Additionally, it is neither induced nor impaired 
as such marker of systemic inflammation by corticosteroids or non-steroid therapy. 
These features and the observations made in the present case suggest canine CRP 
measurements to be of clinical value for assessment of treatment efficiency and for an 
early and objective detection of inflammatory relapses during treatment of canine type 
II IMPA. The observed early and treatment-independent detection of inflammatory 
relapses could possibly enable pre-emptive diagnostic measures to be taken to detect 
the cause of the inflammatory stimulus. 
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Introduction 
Monitoring the effect of steroid therapy of immune-mediated diseases may be difficult. 
The clinician mainly has to rely on clinical signs since objective disease markers such 
as white blood cell count, and absolute numbers of neutrophil granulocytes, 
lymphocytes, monocytes and eosinophil granulocytes may be so affected by the steroid 
treatment per se that they are maybe inadequate for reliable monitoring of the effect of 
treatment. Further complicating factors include the well-known side-effects such as 
polyuria, polydipsia and steroid hepatopathy encountered during steroid treatment. 
Thus, an objective disease marker that is not affected by steroid treatment per se could 
potentially be of great value to the clinician when monitoring the response to and effect 
of treatment. 
One such disease marker could be canine C-reactive protein (CRP). Studies on canine 
CRP indicated that it is a clinically useful marker for monitoring fluctuations in 
inflammatory activity during the state of disease (Ndung'u et al., 1991; Otabe et al., 
2000; Martínez-Subiela et al., 2002; Jergens et al., 2003), to assess the effect of 
therapy (Jergens et al., 2003; Martínez-Subiela et al., 2003) and finally, the CRP acute 
phase response seemed neither to be induced (Martínez-Subiela et al., 2004) nor 
altered (Yamamoto et al., 1994) by corticosteroid therapy as well as non-steroid 
therapy (Hulton et al., 1985). This should make CRP feasible for the monitoring of the 
inflammatory activity during corticosteroid therapy and thus make CRP a potential 
monitoring marker of the response to therapy and possible inflammatory relapses. 
Validated assays for the determination of canine CRP are commercially available 
(Kjelgaard-Hansen et al., 2003a; Kjelgaard-Hansen et al., 2003b; McGrotty et al., 2004) 
as well as guidelines for clinical decision levels for single (Kjelgaard-Hansen et al., 
2004b) and serially (Kjelgaard-Hansen et al., 2003c) obtained CRP measurements in 
dogs. In this report, we communicate the variations in CRP levels during treatment of a 
type II immune-mediated polyarthritis (IMPA) in a dog. 
 
Case report 
Diagnosis 
A 9-year old, female English Springer Spaniel was referred to the Small Animal 
Veterinary Teaching Hospital, Department of Small Animal Clinical Sciences, The 
Royal Veterinary and Agricultural University, Denmark with a history of weight-loss, 
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lethargy, intermittent lameness, generalized lymphadenopathy and recurrent febrile 
episodes during the preceding 8 weeks despite antibiotic and anti-inflammatory steroid 
treatment at dosage. Clinical investigation revealed depression, pyrexia (39.9 ˚C), 
lameness, reluctance to stand and joint pain in multiple joints. Diagnostic procedures 
included complete blood count (CBC) and biochemical profile, urinalysis and 
cytological evaluation of synovial fluid as well as lymph nodes. The CBC and 
biochemical profile revealed a regenerative anaemia characterized by spherocytosis 
and autoagglutination. Lymph node and joint cytology revealed reactive 
lymphadenopathy and neutrophilic inflammation in all joints sampled with Ehrlichia 
spp.-like inclusions in occasional neutrophils. A diagnosis of type II IMPA and immune-
mediated haemolytic anaemia (IMHA) was made and antibiotic therapy (doxycycline 10 
mg/kg sid [Ronaxan Vet.®, Merial, Lyon, France]) was initiated. To further confirm 
Ehrlichia spp. infection and rule out other potential suspect causes of IMHA and type II 
IMPA, thoracic radiographs, abdominal ultrasound, PCR tests for Canine distemper 
virus, Ehrlichia spp., serum antibody titer-tests for Borrelia spp., Bartonella spp. and 
Babesia spp. and anti-nuclear antibody test were performed. All were unremarkable. A 
serum antibody titer for Ehrlichia spp. was, however, positive (IgG titer 1:640). Based 
on the clinical and paraclinical examinations, the dog was considered to suffer from 
IMHA and a type II IMPA secondary to an Ehrlichia spp. infection. 
Immunosuppressive therapy (prednisolone 1.0 mg/kg tid [Prednisolonacetat DAK, 
Nycomed, Roskilde, Denmark]) and analgesic therapy (buprenorphine 0.015 mg/kg sid 
for 2 days [Buprenorfin 1A Farma, 1A Farma, Albertslund, Denmark]) were initiated 
together with protective treatment of the gastric mucosa (sucralfate [Antepsin®, Orion 
Corporation, Espoo, Finland] and misoprostol [Cytotec®, Pharmacia Ltd. Morpeth, 
England]). Antibiotic therapy (doxycycline 10 mg/kg sid) was continued. 
 
Follow-up 
In the follow-up period, the dog was monitored by means of weekly to bi-weekly clinical 
examinations and CBC or if the owner observed symptoms of excessive 
immunosuppression (secondary infection), insufficient immunosuppression (symptoms 
of polyarthritis) or steroid associated adverse effects. 
The dosage of corticosteroid was regulated throughout the follow-up period in an 
attempt to titrate the dosage to an acceptable clinical outcome regarding symptoms of 
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the immune-mediated disease and side-effects of therapy (Figure 1). The dog had 
several periods with relapse of clinical symptoms of polyarthritis (Figure 1) mainly in 
relation to tapering of the corticosteroid therapy, suggesting insufficient 
immunosuppression. Azathioprine (2.0 mg/kg/day [Imurel®, Glaxo Wellcome GmbH & 
Co., Bad Oldesloe, Germany]) was included in the therapy regimen from day 105 in 
combination with prednisolone to possibly lower the necessary dose of prednisolone as 
the dog developed unacceptable degrees of steroid associated adverse effects at the 
immunosuppressive dosage needed to eliminate clinical symptoms of IMPA. For 38 
days the dog did well on a combination of prednisolone (0.125-0.5 mg/kg tid) and 
azathioprine (2.0 mg/kg sid), with acceptable degrees of side effects at the lower doses 
of prednisolone. Symptoms of IMPA returned at day 143 and bone marrow suppression 
indicated by panleukopenia (Figure 1B) and thrombocytopenia was observed at day 
170 and the azathioprine dosage was halved. The dog was euthanized at day 189 as 
the owner declined further therapy. The total number of white blood cells (WBC) and 
neutrophils (Figure 1B) were abnormally high from initiation of therapy until day 144 
and day 158, respectively and decreased to leukopenic and neutropenic levels at day 
170. The observed fluctuations of WBC and neutrophil count were not reflecting the 
clinical signs of disease activity (Figure 1B). Serum C-reactive protein (CRP) 
concentrations were measured (Kjelgaard-Hansen et al., 2003a; Kjelgaard-Hansen et 
al., 2004a) in parallel with the CBCs. The CRP values were not disclosed to the 
clinicians and thus, the results were not used for therapy-adjustments or changes in the 
monitoring regimen.  
 
CRP variations during therapy 
The CRP concentration was high at day 0-4 (65-66 mg/L) (Figure 1A) with a steep 
decline to a level within reference range of 13.1 mg/L (Kjelgaard-Hansen et al., 2004b) 
during the period of initial high-dose prednisolone (0.5-1.0 mg/kg tid [day 4-30]). From 
day 30 to 90, where prednisolone dosage was consistently below 0.5 mg/kg tid, CRP 
gradually increased. The rise in CRP preceded the relapse of clinical signs of 
polyarthritis (day 47-49) by approximately 14 days and was persistently high during the 
period of clinical signs. A second equivalent pattern of CRP was observed during the 
second phase of prednisolone dosage titration (day 95-160) with a rapid decline during 
the period of high prednisolone (0.5 mg/kg tid) and an increase shortly after halving the 
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prednisolone dosage, again preceding the relapse of clinical signs by approximately 14 
days. The CRP declined to immeasurable values (from day 160) during the period of 
severe bone marrow suppression where inflammatory activity was most likely impaired 
by a depletion of inflammatory cells, therefore also a depletion of cellular IL-6 release 
necessary for CRP acute phase response induction. Thus, an increase in CRP 
concentration was observed on two occasions where it preceded clinical signs of 
increased inflammatory activity (polyarthritis) by approximately 14 days during periods 
of low prednisolone dosage (below 0.5 mg/kg tid). Additionally, abnormal levels of CRP 
were consistent with the clinical signs of polyarthritis, except just before the late period 
of severe bone marrow suppression. 
 
Discussion 
The observations made in the present case indicated that the variation in canine CRP 
during immunosuppressive therapy in dogs with type II immune-mediated polyarthritis 
could be useful as an objective early marker of changes in inflammatory activity. This 
could have a positive effect on the case management of type II IMPA by possibly 
enabling early assessment of treatment efficiency, unbiased by treatment itself and 
enabling early indications of undesirable inflammatory activity, due to either relapses of 
disease or the presence of secondary stimulus. These applications are sustained by 
previous reported features of canine CRP: C-reactive protein is a non-specific marker, 
regarding the cause of inflammation. Thus, a decrease in concentration during 
treatment indicates either an effect on the cause of inflammation or a direct medical 
down-regulation of the inflammatory activity (Ndung'u et al., 1991; Jergens et al., 2003; 
Martínez-Subiela et al., 2003; Kumagai et al., 2004). In contrast, an increase in CRP 
concentration during treatment indicates increased inflammatory activity, due to 
increased disease activity or any possible secondary inflammatory stimulus (Caspi et 
al., 1987; Ndung'u et al., 1991; Jergens et al., 2003). Finally, the  CRP response is 
neither modulated nor induced directly by steroid as well as non-steroid drugs (Hulton 
et al., 1985; Yamamoto et al., 1994; Martínez-Subiela et al., 2004). The CBC seemed 
to be adversely biased by both the steroid and cytotoxic treatment regimen, as could 
be expected, and thus, the observed fluctuations were not reflecting the inflammatory 
activity of the disease, as detected by clinical signs of the IMPA in a clinically useful 
manner (Figure 1B). 
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Canine IMPA is subgrouped into 4 groups according to either the absence of defined 
associations (type I), associations with infection (type II), associations with 
gastrointestinal tract disease (type III) and association with neoplasia (type IV) (Bennet, 
1987). Infections of Ehrlichia spp. are reported as a cause of type II IMPA in dogs 
(Cowell et al., 1988; Skotarczak, 2003) where it is assumed that the infectious process 
provides an antigenic source for immune complex formation, and either the antigen or 
circulating complexes are deposited within the synovium to initiate inflammation by a 
type III hypersensitivity reaction (Bennet and May, 1995). 
In general, the therapeutic regimen of type II IMPA is directed against the infectious 
agent, where recovery from the polyarthritis can be seen upon clearance of the 
infectious agent (Bennet, 1987; Cowell et al., 1988). However, supportive 
immunosuppressive therapy is often part of the regimen to help resolve the joint 
inflammation, using either prednisolone alone (1.0-2.0 mg/kg/day) or in combination 
with cytotoxic drugs such as azathioprine (2.0 mg/kg/day) (Bennet, 1987). When 
clinical signs of polyarthritis have resolved, the dosages are gradually reduced over a 
couple of months and if signs return the dosage is increased (Bennet, 1987). 
Canine ehrlichiosis has 3 distinct phases (Kuehn and Gaunt, 1985; Skotarczak, 2003; 
McQuiston et al., 2003). After an incubation period of 8-20 days, an acute phase 
(duration 1-3 weeks) with non-specific signs of infection is seen, including increased 
CRP concentrations (Rikihisa et al., 1994; Shimada et al., 2002). If untreated, affected 
dogs go into a subclinical phase where they remain seropositive, but clinical signs and 
acute phase response diminish. Finally, a third stage of chronic infection may develop 
with marked weight loss, lymphadenopathy, pyrexia and a possible fatal outcome. After 
the acute phase of canine ehrlichiosis, the infection becomes more persistent to 
antibiotic treatment (Wen et al., 1997) and thus may become a continuous stimulus for 
a type II IMPA regardless of therapy. This possible persistent stimulus for the type II 
IMPA could be the reason for the multiple relapses of clinical signs in the present case. 
The involvement of Ehrlichia spp. in the present diagnosis was based on clinical signs, 
cytological findings and a positive antibody titer against Ehrlichia spp., but a negative 
PCR for Ehrlichia spp. antigen was also obtained. However, negative PCR is induced 
quickly after antibiotic treatment (Lappin, 2003). 
In conclusion, CRP measurements seemed valuable as an early and unbiased marker 
of inflammatory activity during immunosuppressive treatment of type II IMPA in this 
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dog, seemingly providing clinically useful information superior to that of CBC. This 
suggests that CRP could be beneficial to case management when used systematically 
in dogs with immune-mediated diseases, as an early and unbiased marker of treatment 
efficiency and detection of undesired inflammatory activity, due to disease relapses or 
secondary stimuli. 
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Figure 1A. Serum C-reactive protein concentrations (CRP [■]) daily dosages of 
antibiotic and immunosupressive therapy in a dog with type II immune-mediated 
polyarthritis (Doxycycline [♦], Prednisolone [▲] and Azathioprine [▼]) plotted against 
days after referral of patient. Shaded areas are periods with clinical symptoms of 
polyarthritis. 
______________________________________________________________________ 
 
102 
 
Figure 1B. White blood cell count (WBC [■]), neutrophil count [●] and daily dosages of 
antibiotic and immunosupressive therapy in a dog with type II immune-mediated 
polyarthritis (Doxycycline [♦], Prednisolone [▲] and Azathioprine [▼]) plotted against 
days after referral of patient. Shaded areas are periods with clinical symptoms of 
polyarthritis. 
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Objectives 
The aim of the thesis was to investigate the hypothesis that “Canine serum CRP 
measurements are applicable for routine purposes in canine medicine”. 
This was done by means of a set of sub-hypotheses covering the different phases of 
investigating the overall hypothesis: 
• Phase I Analytical investigations 
- The analytical performance of commercially available assays (and 
calibration material) can fulfil recognized objective analytical 
performance standards, regarding imprecision, inaccuracy, total error 
and detection limit, thus determine canine CRP reliably in both the short- 
and long-term. 
• Phase II and III Overlap and Clinical investigations 
- Canine CRP measurements can 
 Discriminate between healthy dogs and different subpopulations 
of diseased dogs or 
 Discriminate between different subpopulations of diseased dogs.  
• Phase IV Outcome and Utility investigations 
- Canine CRP measurements has a positive consequence on the case 
management of individuals or groups of individuals in canine medicine, 
e.g. by either 
 Improving the outcome of a clinical problem 
 Providing equivalent clinically useful information faster than 
established parameters 
 Providing equivalent clinically useful information more cost-
effective than established parameters 
In the following the major results of the investigations are presented, discussed and 
concluded upon in relation to these sub-hypotheses and the main objective of the 
thesis. 
The major findings of the present thesis were the unprecedented validation and 
application of an automated human CRP-TIA for the determination of canine serum 
CRP (Paper II) and the presentation and implementation of an optimized species-
specific IQC to detect clinically important errors of the CRP-TIA (Paper IV). 
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Furthermore, a CRP-ELISA specific for canine CRP was validated for clinical use with 
a few limitations (Paper I), objective analytical performance standards (Paper III) and 
objective clinical decision levels for single (Paper V) and serial CRP measurements 
(Paper III) were reported. Finally, observations were made in a case of type II immune-
mediated polyarthritis that sustained previous reports of a possible positive impact of 
CRP determinations on case management (Paper VI). 
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Phase I – Analytical Investigations 
CRP-TIA 
The major and most significant contribution of the thesis was the identification and 
validation of a fully automated commercially available human CRP turbidimetric 
immunoassay (CRP-TIA) for the determination of canine serum CRP (Paper II). 
Analytical performance 
The analytical performance standards for imprecision, inaccuracy and total error were 
objectively derived, as recommended (Fraser et al., 1992; Petersen et al., 2002), from 
observations on the biological variation of canine serum CRP (Paper III). The main 
purpose of the establishment of analytical performance standards were to ensure that 
neither imprecision, inaccuracy nor the combination (total error) would be of a 
magnitude that could adversely influence a clinical decision based on the reported 
result. A hierarchy of methods to assess such performance standards has been 
established as a consensus agreement of clinical pathologists (Kenny et al., 1999). The 
analytical performance standards derived from observations on biological variation 
were judged to be the best alternative to a direct ‘‘evaluation of the effect of analytical 
performance on clinical outcome in specific clinical settings’’ (Kenny et al., 1999). The 
absolute size of a possible inaccuracy of the assay could not be determined as no 
recognized standard or control materials are available for canine CRP. This is a 
general problem for veterinary acute phase proteins, and work has been initiated to 
solve the problem (Eckersall et al., 1999; Skinner, 2001). Instead attempts to indirectly 
detect a possible inaccuracy of the assay were performed by studying linearity under 
dilution and by comparison to another methodology of canine-specific CRP 
determination. The negative outcome in both methods indicated that no constant or 
proportional inaccuracy of significance were present at time of validation. 
Species-specific Internal Quality Control 
The lack of available canine CRP standards and controls also gave rise to problems 
within the aspect of routine internal quality control (IQC). Internal quality control is 
essential to monitor the everyday and long-term analytical performance to detect 
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possible clinically important errors (Westgard, 2001). The CRP-TIA is based on 
polyclonal goat anti-human CRP antibodies and thus relies on the cross-reactivity of 
the anti-human CRP antibodies towards canine CRP. In addition, the assay uses 
purified human CRP as calibration material and thus, long-term stable determination 
furthermore relies on a stable relative affinity of the polyclonal antibodies towards 
human and canine CRP, respectively. Together these aspects made species-specific 
IQC necessary to monitor and detect any clinically significant fluctuations in analytical 
performance. A method for species-specific IQC was successfully developed and 
implemented for the CRP-TIA (Paper IV) using pooled patient serum as surrogate 
control material. Recommended procedures for optimization and implementation of 
IQC procedures were followed (Petersen et al., 1996; Westgard, 2003) during the 
process. The main purpose of the IQC is to ensure that errors of possible significance 
for the clinical decision is detected and corrected before the result is reported. Another 
important aspect is to reduce the risk of falsely rejecting clinically valid runs, due to too 
stringent IQC procedures (Westgard, 2001). In Paper IV, it was demonstrated that the 
use of the traditional IQC criterion of Levey-Jennings charts would result in three times 
as many falsely rejected runs as the reported optimized procedure for the CRP-TIA, 
resulting in unnecessary waste of time and reagents. In other cases, the traditional 
criterion may not be stringent enough and may result in clinical decisions made on a 
false basis due to undetected errors of clinical importance. Thus, for every laboratory it 
is advisable to plan the IQC at an assay-level to optimize the IQC performance. In the 
absence of available recognized species-specific control material, the use of 
surrogates should be considered, as demonstrated in the present thesis (Paper IV). 
Using such surrogates as control material limits the surveillance of inaccuracy to a 
detection of important fluctuations instead of assessing the absolute level of 
inaccuracy. However, this should be sufficient if the presence of clinically important 
inaccuracies was proven unlikely by other measures at the initiation of the IQC 
procedure, as it was done in Paper II for the CRP-TIA. To the author’s knowledge, no 
previous reports on such systematic approach of optimization of a species-specific IQC 
in veterinary clinical pathology have been published, even though; it is an important 
issue, especially when relying on a heterologous determination. 
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Improvement of analytical performance 
In the case of the CRP-TIA, the sources of variation in analytical performance could 
possibly be limited by using purified canine CRP as calibration material, as this would 
eliminate the dependency of a stable relative cross-reactivity of the antibodies towards 
human and canine CRP, respectively. Preliminary results indicate an improved linearity 
under dilution compared to the observations made in Paper II (unpublished data) and 
other aspects of the performance may also improve, although this again depends on 
the availability of such material. 
CRP-ELISA 
A commercially available canine specific CRP-ELISA was also validated for clinical 
purposes in the present thesis (Paper I), with acceptable within-run analytical 
performance. However, between-run imprecision at high levels of CRP could not meet 
the performance standard, as also observed by others (Martínez-Subiela et al., 2003c). 
In practical terms this would make it necessary to perform additional measures to 
enable clinical use, e.g. to analyze serially obtained samples from the same individual 
together in the same analytical run to eliminate the inter-assay variation and thus, 
ensure reliable monitoring of the CRP level. 
General practicability of assays 
In general, TIA is considered to be superior to ELISA regarding practicability, as a TIA 
makes it possible to run single samples on demand compared to ELISA where batch-
runs are usually necessary (Eckersall et al., 1991). This together with the poorer time-
effectiveness of the CRP-ELISA compared to the automated CRP-TIA makes the CRP-
ELISA an important alternative only if apparatus for running the CRP-TIA is not at hand 
or the CRP-TIA should fail to withhold the clinically acceptable performance in the 
future. 
Automated assays specific for canine CRP have been developed (Eckersall et al., 
1991; Onishi et al., 2000; Kumagai et al., 2004) and these homologous assays should 
be preferred to heterologous assays if analytical performance and practicability are 
equalled. However, an important additional aspect in the assessment of practicability, 
besides automation is general availability and economic costs, especially important 
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when assessing the applicability for wide-spread routine purposes. In these aspects the 
level of practicability of the CRP-TIA is unequalled at the present. 
Conclusions of Phase I 
The validation of a canine specific CRP ELISA (Paper I) and a human CRP-TIA (Paper 
II) for the clinical useful determination of canine serum CRP assessed by means of 
objective analytical performance standards (Paper III) and the successful application of 
a canine-specific IQC including the observation of an excellent long-term analytical 
performance of the CRP-TIA (Paper IV) sustain the hypothesis of phase I in the thesis. 
Phase II and III – Overlap and Clinical Investigations 
As expected, a marked and significant difference in the median-levels of CRP between 
dogs with inflammatory diseases and dogs without systemic inflammation (healthy 
dogs and dogs with a non-inflammatory disorder) were observed in the overlap 
investigations (Paper V). It is well established that CRP is a major acute phase protein 
in dogs and good evidence for an elevated level of canine CRP being consistent with 
increased systemic inflammatory activity (see Introduction).  
Diagnostic properties of canine CRP 
Canine CRP seemingly has a substantial potential as a clinically useful marker of 
systemic inflammatory activity with high diagnostic sensitivity and specificity. C-reactive 
protein is a non-specific marker of systemic inflammation regarding the nature of 
stimulus and the relative concentration seems to relate to the relative inflammatory 
activity of the disease process. These properties facilitate the use of canine CRP in the 
selection of “first-line” tests used in the phase of differential-diagnostic considerations 
of the diseased dog, where it can provide valuable information of possible inflammatory 
involvement. The properties of high diagnostic sensitivity, due to the marked increase 
in a wide range of systemic inflammatory activities and a high diagnostic specificity in 
the detection of inflammation, but being non-specific regarding the nature of stimulus, 
strengthen this applicability. This was in part sustained by the observations in Paper V, 
where a high diagnostic specificity for the CRP-TIA to discriminate between different 
subpopulations of diseased dogs (dogs with or without diseases causing systemic 
inflammation) and between healthy dogs and dogs with diseases causing systemic 
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inflammation could be obtained (cut-off between 16.0-17.8 mg/L). At the reported cut-
off level the high diagnostic specificity was obtained without adversely impairing the 
capability to detect a wide range of inflammatory activity. Optimizing diagnostic 
specificity without impairing the detection of a wide range of inflammatory activity 
observed in various diseases will most likely ensure a high predictive value of a 
positive result under different clinical settings, as also reported for canine CRP by 
others (Riley and Zontine, 1972; Eckersall et al., 1988; Börngen, 1998). 
If the objective is to rule out systemic inflammatory activity, e.g. in health screenings, 
diagnostic sensitivity should be favoured to facilitate high predictive value of a negative 
result. However, an observed low index of individuality for canine CRP (R=0.87), i.e. 
the ratio of intra-individual and inter-individual biological variation seem to impair this 
application (Paper III). The index of individuality can be used to assess the utility of 
population-based reference ranges (and also other population-based clinical decision 
levels) to evaluate single measurements (Harris, 1974). The observed low index of 
individuality characterizes canine CRP as relative tightly controlled within the individual 
compared to the variation observed between individuals, as also observed by others 
(Otabe et al., 1998). Therefore, the use of population-based decision levels are 
insensitive in the detection of small, but to the individual significant changes in CRP 
(Harris, 1974). The properties of canine CRP as an acute phase marker, thus, seem to 
favour its clinical applicability as a confirmative marker of systemic inflammatory activity 
compared to the applicability as an exclusion marker. 
Monitoring properties of canine CRP 
There is also substantial evidence for a correlation between the canine CRP 
concentrations and the activity of the inflammatory process, and that fluctuations of 
CRP during the state of disease is an almost “real-time” marker of the activity (see 
Introduction). This, together with the apparently high diagnostic specificity in detecting 
systemic inflammation and the lack of observed modulatory effects of a wide range of 
common therapeutics (see Introduction), gives canine CRP a potential as an objective 
marker for monitoring inflammatory activity during the state of disease and treatment 
thereof. The critical difference (CD) of canine CRP, i.e. the change in CRP needed 
between two serially obtained samples from the same individual to be significant was 
assessed from observations on biological variation to be 71.7% (Paper III). A similar 
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study on the biological variation of canine CRP also reported the different variance 
components of biological variation (0.82 mg/L, 2.21 [mg/L]2, 1.74 [mg/L]2 and 0.74 
[mg/L]2 for overall arithmetic mean and for intra-individual, inter-individual and 
analytical variance, respectively)  (Martínez-Subiela et al., 2003b) corresponding to a 
CD as high as 583%. Unfortunately, a CD that high also indicates that outlying 
observations may have been included in the study causing biased estimates of the 
variance components and thus, a biased estimate of the critical difference (Franzini, 
1998). 
The CD will apply as an objective clinical decision level to both monitor clinically 
significant increases and decreases of CRP to detect either increased or decreased 
inflammatory activity between two samples (Clark and Fraser, 1993). It can also be 
used to evaluate differences between multiple serially obtained samples and this 
slightly more complicated statistical matter is described elsewhere (Kroll, 2002). 
Conclusions of Phase II and III 
The observations made in Paper III and V of the present thesis, together with the 
substantial information from other studies assessing CRP values in health and disease 
and investigating the clinical useful discriminative properties of canine CRP (see 
Introduction) sustain the presence of clinically useful discriminatory abilities of canine 
CRP as hypothesised. The observations made in Paper III and V provide clinical 
decision levels to evaluate serial and single measurements of canine CRP, 
respectively. The properties of canine CRP were observed to favour its clinical 
applicability as a confirmative marker of systemic inflammatory activity, rather than an 
exclusion marker. 
Phase IV – Outcome and Utility Investigations 
The essence of Phase IV is enclosed in the statement of Zweig and Robertson (1982): 
“A laboratory test is clinically useful only if it successfully answers a question of 
consequence to patient management”. Phase IV is only applied if the previous phases 
of the applicability assessment were successfully answered to, but, in the end, if the 
hypothesis of the final phase: “Canine CRP measurements have a positive 
consequence on the case management of individuals or groups of individuals in canine 
medicine” is rejected the results of the previous phases are of no significance. 
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The introduction of novel routine parameters can improve case management in several 
ways, e.g. by: 
• Improving clinical outcome 
• Providing equivalent clinically useful information faster than established 
parameters 
• Providing equivalent clinically useful information more cost-effective than 
established parameters 
Information on the effect on clinical outcome of established canine inflammatory 
markers is scarcely available. One study assessing the diagnostic sensitivity and 
specificity of traditional inflammatory markers (rectal temperature, CBC, band 
neutrophil concentration, heart rate and respiratory rate) in detecting canine sepsis, 
which per se includes an APR, identified CBC and band neutrophil number as the best 
performing single markers (Hauptman et al., 1997). The best detection of sepsis was, 
however, obtained using all parameters in a combined serial and parallel setting with 
observed diagnostic sensitivities and specificities of 83%-97% and 64%-77%, 
respectively (Hauptman et al., 1997). An observed clinical performance to which the 
observed diagnostic sensitivities and specificities of canine CRP seem at least 
comparable, especially regarding diagnostic specificity (Paper V). This can in part be 
explained by the stress-lability (e.g. affected by endogenous corticosteroids and 
catecholamines) of these traditional markers of systemic inflammation, except for band 
neutrophils, whereas CRP at the present state of knowledge is only induced by 
proinflammatory hypercytokinaemia. 
It is not clear whether an increase in CRP or an altered CBC are the first appearing 
sign of an APR  (Yamamoto et al., 1993b; Yamashita et al., 1994; Burton et al., 1994; 
Otabe et al., 2000; Higgins et al., 2003). Thus, it should be investigated whether the 
information of CRP and CBC could be complementary in the early detection of an APR 
and as a conglomerate improve the case management of patients during the per-acute 
inflammatory state of disease. 
The results of Paper VI suggested an improved case management of type II immune-
mediated polyarthritis (IMPA) by means of CRP measurements. Canine serum CRP 
seemed to be an early objective marker of the relative inflammatory activity. In the 
absence of secondary causes of increased inflammatory activity, CRP was a marker of 
treatment efficiency during steroid, antibiotic and cytotoxic treatment of the IMPA and 
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furthermore seemed to be capable of early objective detection of relapses of clinical 
symptoms. In that case, diagnostic measures should be taken to exclude secondary 
causes of elevated inflammatory activity. When monitoring the effect of steroid therapy 
of immune-mediated polyarthritis, the clinician mainly has to rely on clinical signs since 
objective disease markers such as white blood cell count, and absolute numbers of 
neutrophil granulocytes, lymphocytes, monocytes and eosinophil granulocytes may be 
so affected by the steroid treatment per se that they are maybe inadequate for reliable 
monitoring of the effect of treatment. The observations made in Paper VI sustained 
previous reported observations, where canine CRP was identified as an objective 
marker of treatment efficiency during treatment of leishmaniasis (Martínez-Subiela et 
al., 2003a), as a marker of final treatment efficiency of canine inflammatory bowel 
disease (Jergens et al., 2003) and as an indicator of parasitaemic relapses during 
insufficient treatment of experimental Trypanosoma brucei infections (Ndung'u et al., 
1991). The early and objective detection of inflammatory relapses during treatment of 
IMPA, as indicated in Paper VI, has the potential to improve case management. The 
detection preceded the reappearance of clinical symptoms and therefore enables an 
earlier initiation of diagnostic measures to identify the source of the change in 
inflammatory activity. 
Finally, serum CRP possesses superior storage properties compared to the cellular 
markers of inflammation (Vogelaar et al., 2002), e.g. making retrospective diagnostic 
measures possible by reanalysis on stored serum. 
Conclusions of Phase IV 
Through evaluation of previously reported clinical findings on the utility of canine CRP 
in graduating, detecting and monitoring the appearance and variation in inflammatory 
activity, canine CRP measurements must be assumed to have a positive effect on the 
outcome to case management under various specific clinical settings, as exemplified 
by the findings in Paper VI. The hypothesis of Phase IV was therefore sustained. 
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General Conclusions 
Based on the observations made in this thesis and those previously reported on canine 
CRP it can be concluded that canine CRP measurements are applicable for routine 
purposes in canine medicine. This hypothesis was thoroughly tested throughout the 
thesis in a stepwise manner, where the measurement of canine serum CRP answered 
positively to all phases. 
The major contribution of the present thesis to the assessment of the applicability of 
canine CRP for clinical purposes can be summarized by the following conclusions: 
• Canine CRP can be measured reliably and with high practicability by means of 
a commercially available automated CRP-TIA designed for the determination of 
human CRP concentrations with excellent analytical performance during short- 
and long-term evaluation as assessed by objective analytical performance 
standards (Paper II, III, and IV). An application which is unprecedented 
regarding canine CRP and which by means of enhanced practicability and 
availability compared to other methods for canine CRP determination should 
facilitate routine application. 
• Canine CRP can be measured reliably by means of a canine CRP specific 
ELISA fulfilling objective analytical performance standards except for inter-
assay imprecision (Paper I). An important alternative to the CRP-TIA during 
circumstances where this could be non-applicable. 
• A simple species-specific IQC optimized for detection of clinically important 
errors and minimization of false-rejection can be implemented for the CRP-TIA 
to ensure control of the everyday and long-term analytical performance by 
means of pooled patient serum as surrogates for the lacking recognized 
standards and control material (Paper IV). To the author’s knowledge, there are 
no previous reports of such optimized species-specific IQC in veterinary clinical 
pathology and the method presented in Paper IV can with advantage be used 
for other veterinary assays to ensure species-specific monitoring and detection 
of clinically important errors. 
• The properties of canine CRP were observed to favour the use of CRP 
measurements as a confirmative parameter in detecting systemic inflammatory 
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activity and clinical decision levels optimized for this purpose were established 
(Paper III and V). 
• An objective clinical decision level for evaluation of differences between serially 
obtained canine CRP measurements was established (Paper III). 
• Observations were made during corticosteroid treatment in a case of type II 
immune-mediated polyarthritis that sustained the previous observations of a 
positive impact of canine CRP measurements on case management in specific 
clinical settings by providing clinical useful objective information on 
inflammatory activity, otherwise not obtainable (Paper VI). 
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Perspectives 
In this thesis a thorough systematic evaluation of the different aspects of the 
applicability of CRP for routine purposes in canine medicine was performed. A 
continuum of objectively derived information on these aspects is thus now available to 
sustain previously reported findings regarding canine CRP. In perspective, this will 
hopefully help to increase and spread the use of canine CRP as a routine parameter 
for diagnostic, monitoring and possibly screening purposes. A routine implementation 
of canine CRP will automatically enhance the knowledge of it, as measurements will no 
longer be performed on a material as selected as during specific investigations. This 
will most likely lead to new hypothesis of the applicability of canine CRP 
measurements, as it did in human medicine regarding a possible link to atherosclerosis 
and –thrombosis (Manolov et al., 2003; Jialal et al., 2004). An interesting aspect here 
could be the evaluation, diagnosis and monitoring of inflammation-related 
coagulopathies. 
Regarding quality control, there is a mere need for available recognised control 
material to ensure comparability between results obtained throughout a geographical 
area and to facilitate wide-spread appropriate IQC. The approach to implement a local 
species-specific IQC in the lack of recognised species-specific control material for 
canine CRP assays, as presented in Paper IV, can be used for other veterinary assays 
also. All veterinary assays should optimally be subdued to species-specific IQC, but to 
a higher degree in assays relying on heterologous determination of species-specific 
molecules, e.g. proteins. The method presented in paper IV is applicable to fill the 
period until the work to establish species-specific control materials (Eckersall et al., 
1999; Skinner, 2001) is finished. 
No doubt, that additional testing of clinical hypotheses is needed to widen the spectre 
of possible applications of canine CRP measurements and to identify the specific 
clinical entities that will benefit the most of its application. To perform the latter 
properly, there is a mere need for appropriately designed prospective randomized 
controlled studies on the effect of canine CRP measurements on the outcome of 
specific clinical entities, which would be the next logical step to enhance the evaluation 
of the applicability of canine CRP measurements.  
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The detection and classification of naturally occurring sepsis in dogs could be an 
interesting field where serum CRP measurements could facilitate the investigations. In 
human medicine there is a focus on that imbalances in the relative level of pro-
inflammatory cytokines (e.g. IL-6) and the compensatory anti-inflammatory cytokines 
(e.g. IL-10) during sepsis may have a casual link to the development and outcome of 
sepsis (Gogos et al., 2000; Loisa et al., 2003; Carrigan et al., 2004). However, as 
measurements of canine IL-6 requires delicate bioassays and canine CRP has been 
reported to follow the IL-6 response (Yamashita et al., 1994) and reflects the extent of 
the inflammatory activity, CRP may be useful as a IL-6 surrogate to detect and classify 
possible imbalances in the inflammatory response to canine sepsis. 
_____________________________________________________________________ 
 119 
REFERENCES 
Abernethy,T.J. and O.T.Avery, 1941: The occurence during acute infections of a protein not 
normally present in the blood. I. Distribution of the reactive protein in patients' sera and 
the effect of calcium on the flocculation reaction with C-polysaccharide of 
pneumococcus. Journal of Experimental Medicine 73, 173-182. 
Agrawal,A., A.K.Shrive, T.J.Greenhough and J.E.Volanakis, 2001: Topology and structure of 
the C1q-binding site on C-reactive protein. Journal of Immunology 166, 3998-4004. 
Anderson,H.C. and M.McCarty, 1950: Determination of C-reactive protein in the blood as a 
measure of the activity of the disease process in acute rheumatic fever. American 
Journal of Medicine 8, 445-455. 
Anderson,N.R., K.Chatha, M.R.Holland and R.Gama, 2003: Effect of sample tube type and time 
to separation on in vitro levels of C-reactive protein. British Journal of Biomedical 
Science 60, 164-165. 
Anderson,N.R., K.Chatha, M.R.Holland and R.Gama, 2004: Interference caused by the 
contents of serum separator tubes in the Vitros CRP assay [Letter]. Annals of Clinical 
Biochemistry 41, 171-172. 
Andersson,M., M.Stenstrom, M.Vatne, E.Sevelius and L.Jonsson, 1998: Disease-related 
variations of the glycosylation of haptoglobin in the dog. Journal of Comparative 
Pathology 119, 227-238. 
Baltz,M.L., F.C.de Beer, A.Feinstein, E.A.Munn, C.P.Milstein, T.C.Fletcher, J.F.March, J.Taylor, 
C.Bruton, J.R.Clamp, A.J.S.Davies and M.B.Pepys, 1982: Phylogenetic aspects of C-
reactive protein and related proteins. Annals of the New York Academy of Science 389, 
49-75. 
Baumann,H. and J.Gauldie, 1994: The acute phase response. Immunology Today 15, 74-80. 
Bharadwaj,D., M.P.Stein, M.Volzer, C.Mold and T.W.Du Clos, 1999: The major receptor for C-
reactive protein on leukocytes is fcgamma receptor II. Journal of Experimental Medicine 
190, 585-590. 
Borer,L.R., J.E.Peel, W.Seewald, P.Schawalder and D.E.Spreng, 2003: Effect of carprofen, 
etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis. American 
Journal of Veterinary Research 64, 1429-1437. 
Börngen,S., 1998: Nachweis von C-reaktivem protein beim Hund [Dissertation]. Institut für 
Bakteriologie und Mykologie der Veterinärmedizinischen Fakultät der Universität 
Leipzig, Germany. pp. 1-95. 
Bossuyt,P.M., J.B.Reitsma, D.E.Bruns, C.A.Gatsonis, P.P.Glasziou, L.M.Irwig, J.G.Lijmer, 
D.Moher, D.Rennie and H.C.De Vet, 2003: Towards complete and accurate reporting of 
studies of diagnostic accuracy: the STARD initiative. Clinical Chemistry and Laboratory 
Medicine 41, 68-73. 
_____________________________________________________________________ 
 120 
Burton,S.A., D.J.Honor, A.L.Mackenzie, P.D.Eckersall, R.J.F.Markham and B.S.Horney, 1994: 
C-reactive protein concentration in dogs with inflammatory leukograms. American 
Journal of Veterinary Research 55, 613-618. 
Carrigan,S.D., G.Scott and M.Tabrizian, 2004: Toward Resolving the Challenges of Sepsis 
Diagnosis. Clinical Chemistry   
Casals,C., A.Varela, M.L.Ruano, F.Valino, J.Perez-Gil, N.Torre, E.Jorge, F.Tendillo and 
J.L.Castillo-Olivares, 1998: Increase of C-reactive protein and decrease of surfactant 
protein A in surfactant after lung transplantation. American Journal of Respiratory and 
Critical Care Medicine 157, 43-49. 
Caspi,D., M.L.Baltz, F.Snel, E.Gruys, D.Niv, R.M.Batt and E.A.Munn, 1984: Isolation and 
characterization of C-reactive protein from the dog. Immunology 53, 307-313. 
Caspi,D., F.W.J.J.Snel, R.M.Batt, D.Bennett, G.R.Rutteman, E.G.Hartman, M.L.Baltz, E.Gruys 
and M.B.Pepys, 1987: C-reactive protein in dogs. American Journal of Veterinary 
Research 48, 919-921. 
Castell,J.V., M.J.Gomez-Lechon, M.David, T.Andus, T.Geiger, R.Trullenque, R.Fabra and 
P.C.Heinrich, 1989: Interleukin-6 is the major regulator of acute phase protein synthesis 
in adult human hepatocytes. FEBS Letters 242, 237-239. 
Chang,C.Y., J.Y.Lu, T.I.Chien, J.T.Kao, M.C.Lin, P.C.Shih and S.N.Yan, 2003: Interference 
caused by the contents of serum separator tubes in the Vitros CRP assay. Annals of 
Clinical Biochemistry 40, 249-251. 
Clark,G.H. and C.G.Fraser, 1993: Biological variation of acute phase proteins. Annals of Clinical 
Biochemistry 30, 373-376. 
Concannon,P.W., T.Gimpel, L.Newton and V.D.Castracane, 1996: Postimplantation increase in 
plasma fibrinogen concentration with increase in relaxin concentration in pregnant dogs. 
American Journal of Veterinary Research 57, 1382-1385. 
Conner,J.G., P.D.Eckersall, J.Ferguson and T.A.Douglas, 1988: Acute phase response in the 
dog following surgical trauma. Research in Veterinary Science 45, 107-110. 
Deegan,O., K.Walshe, K.Kavanagh and S.Doyle, 2003: Quantitative detection of C-reactive 
protein using phosphocholine-labelled enzyme or microspheres. Analytical Biochemistry 
312, 175-181. 
Dillman,R.C. and E.H.Coles, 1966: A canine serum fraction analogous to human C-reactive 
protein. American Journal of Veterinary Research 27, 1769-1775. 
Dinarello,C.A., 1997: Interleukin-1. Cytokine & Growth Factor Reviews 8, 253-265. 
Dong,Q. and J.R.Wright, 1996: Expression of C-reactive protein by alveolar macrophages. 
Journal of Immunology 156, 4815-4820. 
Dougherty,T.J., H.Gewurz and J.N.Siegel, 1991: Preferential binding and aggregation of rabbit 
C-reactive protein with arginine-rich proteins. Molecular Immunology 28, 1113-1120. 
_____________________________________________________________________ 
 121 
Du Clos,T.W., L.T.Zlock, P.S.Hicks and C.Mold, 1994: Decreased autoantibody levels and 
enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clinical 
Immunology and Immunopathology 70, 22-27. 
Du Clos,T.W., L.T.Zlock and R.L.Rubin, 1988: Analysis of the binding of C-reactive protein to 
histones and chromatin. Journal of Immunology 141, 4266-4270. 
Eckersall,P.D. and J.G.Conner, 1988: Bovine and canine acute phase proteins. Veterinary 
Research Communications 12, 169-178. 
Eckersall,P.D., J.G.Conner and J.Harvie, 1991: An immunoturbidimetric assay for canine C-
reactive protein. Veterinary Research Communications 15, 17-24. 
Eckersall,P.D., J.G.Conner and H.Parton, 1989: An enzyme-linked immunosorbent assay for 
canine C-reactive protein. Veterinary Record 124, 490-491. 
Eckersall,P.D., S.Duthie, M.J.M.Toussaint, E.Gruys, P.Heegaard, M.Alava, C.Lipperheide and 
F.Madec, 1999: Standardisation of diagnostic assays for animal acute phase proteins. 
Advances in Veterinary Medicine 41, 643-655. 
Eckersall,P.D., M.J.A.Harvey, J.M.Ferguson, J.P.Renton, D.A.Nickson and J.S.Boyd, 1993: 
Acute phase proteins in canine pregnancy (canis familiaris). Journal of Reproduction 
and Fertility S47, 159-164. 
Eckersall,P.D., H.Parton, J.G.Conner, A.S.Nash, T.Watson, T.A.Douglas and D.J.Blackmore, 
1988: Acute phase reactants in diseases of dog and cattle. In: Animal clinical 
biochemistry of the future, 1 ed. (editors: Blackmore,D.J. and P.D.Eckersall), 
Cambridge University Press, Cambridge, UK. pp. 225-230. 
Egenhofer,C., K.Alsdorff, K.Fehsel and V.Kolb-Bachofen, 1993: Membrane-associated C-
reactive protein on rat liver macrophages is synthesized within the macrophages, 
expressed as neo-C-reactive protein and bound through a C-reactive protein-specific 
membrane receptor. Hepatology 18, 1216-1223. 
Fiedel,B.A., R.M.Simpson and H.Gewurz, 1982: Effects of C-reactive protein (CRP) on platelet 
function. Annals of the New York Academy of Science 389, 263-273. 
Filep,J. and E.Foldes-Filep, 1989: Effects of C-reactive protein on human neutrophil 
granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-
activating factor. Life Science 44, 517-524. 
Filep,J.G., F.Herman, E.Kelemen and E.Foldes-Filep, 1991: C-reactive protein inhibits binding 
of platelet-activating factor to human platelets. Thrombosis Research 61, 411-421. 
Fransson,B.A., E.Karlstam, A.Bergstrom, A.S.Lagerstedt, J.S.Park, M.A.Evans and C.A.Ragle, 
2004: C-reactive Protein in the Differentiation of Pyometra From Cystic Endometrial 
Hyperplasia/Mucometra in Dogs. Journal of the American Animal Hospital Association 
40, 391-399. 
Franzini,C., 1998: Need for correct estimates of biological variation: The example of C-reactive 
protein [letter]. Clinical Chemistry and Laboratory Medicine 36, 131-132. 
Fraser,C.G., 2001: Biological variation: From principles to practice. AACC Press, Washington, 
USA. pp. 1-151. 
_____________________________________________________________________ 
 122 
Fraser,C.G., P.H.Petersen, C.Ricos and R.Haeckel, 1992: Proposed quality specifications for 
imprecision and inaccuracy of analytical systems for clinical chemistry. European 
Journal of Clinical Chemistry and Clinical Biochemistry 30, 311-317. 
Fujimoto,T., Y.Sato, N.Sasaki, R.Teshima, K.Hanaoka and S.Kitani, 2003: The canine mast cell 
activation via CRP. Biochemical and Biophysical Research Communications 301, 212-
217. 
Fujise,H., 1992: Availability of acute phase protein for clinical examination in domestic animals: 
canine C-reactive protein. Journal of the Japan Veterinary Medical Association 45, 731-
737. 
Gabay,C. and I.Kushner, 1999: Acute-phase proteins and other sytemic responses to 
inflammation. The New England Journal of Medicine 340, 448-454. 
Gershov,D., S.Kim, N.Brot and K.B.Elkon, 2000: C-Reactive protein binds to apoptotic cells, 
protects the cells from assembly of the terminal complement components, and sustains 
an antiinflammatory innate immune response: implications for systemic autoimmunity. 
Journal of Experimental Medicine 192, 1353-1364. 
Gogos,C.A., E.Drosou, H.P.Bassaris and A.Skoutelis, 2000: Pro- versus anti-inflammatory 
cytokine profile in patients with severe sepsis: a marker for prognosis and future 
therapeutic options. Journal of Infectious Diseases 181, 176-180. 
Gotschlich,E.C., 1962: Occurence of a substance analogous to C-reactive protein in acute 
phase dog sera. Federation Proceedings 21, 14. 
Gotschlich,E.C. and G.M.Edelman, 1965: C-reactive protein: a molecule composed of subunits. 
Proceedings of the National Academy of Science of the United States of America 54, 
558-566. 
Gould,J.M. and J.N.Weiser, 2001: Expression of C-reactive protein in the human respiratory 
tract. Infection and Immunity 69, 1747-1754. 
Han,K.H., K.H.Hong, J.H.Park, J.Ko, D.H.Kang, K.J.Choi, M.K.Hong, S.W.Park and S.J.Park, 
2004: C-reactive protein promotes monocyte chemoattractant protein-1-mediated 
chemotaxis through upregulating CC chemokine receptor 2 expression in human 
monocytes. Circulation 109, 2566-2571. 
Hansson,L.-O., 1996: C-reactive protein in clinical practice - with special regard to infectious 
diseases [Dissertation]. Karolinska Institute, Stockholm, Sweden. pp. 1-86. 
Harris,E.K., 1974: Effects of intra- and interindividual variation on the appropriate use of normal 
ranges. Clinical Chemistry 20, 1535-1542. 
Hattori,Y., M.Matsumura and K.Kasai, 2003: Vascular smooth muscle cell activation by C-
reactive protein. Cardiovascular Research 58, 186-195. 
Hauptman,J.G., R.Walshaw and N.B.Olivier, 1997: Evaluation of the sensitivity and specificity of 
diagnostic criteria for sepsis in dogs. Veterinary Surgery 26, 393-397. 
Hayashi,S., T.Jinbo, K.Iguchi, M.Shimizu, T.Shimada, M.Nomura, Y.Ishida and S.Yamamoto, 
2001: A comparison of the concentrations of C-reactive protein and alpha1-acid 
_____________________________________________________________________ 
 123 
glycoprotein in the serum of young and adult dogs with acute inflammation. Veterinary 
Research Communications 25, 117-126. 
Higgins,M.A., B.R.Berridge, B.J.Mills, A.E.Schultze, H.Gao, G.H.Searfoss, T.K.Baker and 
T.P.Ryan, 2003: Gene expression analysis of the acute phase response using a canine 
microarray. Toxicological sciences 74, 470-484. 
Hoier,R. and A.L.Jensen, 1993: Evaluation of an enzyme linked immunosorbent assay (ELISA) 
for determination of insulin in dogs. Journal of Veterinary Medicine. A, Physiology, 
Pathology and Clinical Medicine 40, 26-32. 
Hokama,Y., R.Tam, W.Hirano and L.Kimura, 1974: Significance of C-reactive protein binding by 
lecithin: a simplified procedure for CRP isolation. Clinica Chimica Acta 50, 53-62. 
Hulton,N.R., D.J.Johnson and D.W.Wilmore, 1985: Limited effects of prostaglandin inhibitors in 
Escherichia coli sepsis. Surgery 98, 291-297. 
Hurlimann,J., G.J.Thorbecke and G.M.Hochwald, 1966: The liver as the site of C-reactive 
protein formation. Journal of Experimental Medicine 123, 365-378. 
Jabs,W.J., B.A.Logering, P.Gerke, B.Kreft, E.M.Wolber, M.H.Klinger, L.Fricke and J.Steinhoff, 
2003: The kidney as a second site of human C-reactive protein formation in vivo. 
European Journal of Immunology 33, 152-161. 
Jensen,A.L., M.Bomholt and L.Moe, 2001: Preliminary evaluation of a particle enhanced 
turbidometric immunoassay (PETIA) for the determination of serum cystatin C-like 
immunoreactivity in dogs. Veterinary Clinical Pathology 30, 86-90. 
Jergens,A.E., C.A.Schreiner, D.E.Frank, Y.Niyo, F.E.Ahrens, P.D.Eckersall, T.J.Benson and 
R.Evans, 2003: A scoring index for disease activity in canine inflammatory bowel 
disease. Journal of Veterinary Internal Medicine 17, 291-297. 
Jialal,I., S.Devaraj and S.K.Venugopal, 2004: C-reactive protein: risk marker or mediator in 
atherothrombosis? Hypertension 44, 6-11. 
Kampschmidt,R.F. and H.F.Upchurch, 1974: Effect of leukocytic endogenous mediator on 
plasma fibrinogen and haptoglobin. Proceedings of the Society for Experimental Biology 
and Medicine 146, 904-907. 
Kenny,D., C.G.Fraser, P.H.Petersen and A.Kallners, 1999: Consensus agreement. 
Scandinavian Journal of Clinical Laboratory Investigation 59, 585. 
Kishimoto,T., 1989: The biology of interleukin-6. Blood 74, 1-10. 
Kluft,C. and M.P.de Maat, 2002: Sensitive markers of inflammation make it possible to study the 
chronic process: the rise of interest in low levels of C-reactive protein. Vascular 
pharmacology 39, 99-104. 
Koj,A., 1985: Cytokines regulating acute inflammation and synthesis of acute phase proteins. 
Blut 51, 267-274. 
Kolb-Bachofen,V., N.Puchta-Teudt and C.Egenhofer, 1995: Expression of membrane-
associated C-reactive protein by human monocytes: indications for a selectin-like 
activity participating in adhesion. Glycoconjugate Journal 12, 122-127. 
_____________________________________________________________________ 
 124 
Kroll,M.H., 2002: Evaluating sequential values using time-adjusted biological variation. Clinical 
Chemistry and Laboratory Medicine 40, 499-504. 
Kumagai,K., H.Nakashima and K.Saku, 2004: The HMG-CoA reductase inhibitor atorvastatin 
prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. 
Cardiovascular Research 62, 105-111. 
Kuribayashi,T., T.Shimada, M.Matsumoto, K.Kawato, T.Honjyo, M.Fukuyama, Y.Yamamoto and 
S.Yamamoto, 2003: Determination of serum C-reactive protein (CRP) in healthy beagle 
dogs of various ages and pregnant beagle dogs. Experimental Animals 52, 387-390. 
Kushner,I. and G.Feldmann, 1978: Control of the acute phase response. Demonstration of C-
reactive protein synthesis and secretion by hepatocytes during acute inflammation in 
the rabbit. Journal of Experimental Medicine 148, 466-477. 
Kushner,I., M.Ganapathi and D.Schultz, 1989: The acute phase response is mediated by 
heterogeneous mechanisms. Annals of the New York Academy of Science 557, 19-29. 
Kushner,I., W.N.Ribich and J.B.Blair, 1980: Control of the acute-phase response. C-reactive 
protein synthesis by isolated perfused rabbit livers. Journal of Laboratory and Clinical 
Medicine 96, 1037-1045. 
Kuta,A.E. and L.L.Baum, 1986: C-reactive protein is produced by a small number of normal 
human peripheral blood lymphocytes. Journal of Experimental Medicine 164, 321-326. 
Liu,Q., G.Djuricin, C.Nathan, P.Gattuso, R.A.Weinstein and R.A.Prinz, 2000: The effect of 
interleukin-6 on bacterial translocation in acute canine pancreatitis. International Journal 
of Pancreatology 27, 157-165. 
Loisa,P., T.Rinne, S.Laine, M.Hurme and S.Kaukinen, 2003: Anti-inflammatory cytokine 
response and the development of multiple organ failure in severe sepsis. Acta 
Anaesthesiologica Scandinavica 47, 319-325. 
Mackiewicz,A., I.Kushner and H.Baumann, 1993: Acute phase proteins: Molecular biology, 
Biochemistry, and clinical applications. CRC Press, London, UK. pp. 3-665. 
MacLeod,C.M. and O.T.Avery, 1941: The occurence during acute infections of a protein not 
normally present in the blood. III. Immunological properties of the C-reactive protein and 
its differentation from normal blood proteins. Journal of Experimental Medicine 73, 191-
200. 
Manolov,D.E., W.Koenig, V.Hombach and J.Torzewski, 2003: C-reactive protein and 
atherosclerosis. Is there a causal link? Histology and Histopathology 18, 1189-1193. 
Martínez-Subiela,S., L.J.Bernal and J.J.Ceron, 2003a: Serum concentrations of acute-phase 
proteins in dogs with leishmaniosis during short-term treatment. American Journal of 
Veterinary Research 64, 1021-1026. 
Martínez-Subiela,S., P.M.Dolores and J.J.Ceron, 2004a: Influence of different preanalytical 
factors on an ELISA for canine CRP determination [Abstract]. Veterinary Clinical 
Pathology [In Press]. 
Martínez-Subiela,S., P.J.Ginel and J.J.Ceron, 2004b: Effects of different glucocorticoid 
treatments on serum acute phase proteins in dogs. Veterinary Record 154, 814-817. 
_____________________________________________________________________ 
 125 
Martínez-Subiela,S., F.Tecles and J.J.Ceron, 2003b: Critical differences of acute phase proteins 
in canine serum samples. Veterinary Journal 166, 233-237. 
Martínez-Subiela,S., F.Tecles, P.D.Eckersall and J.J.Ceron, 2002: Serum concentrations of 
acute phase proteins in dogs with leishmaniasis. Veterinary Record 150, 241-244. 
Martínez-Subiela,S., F.Tecles, M.D.Parra and J.J.Ceron, 2003c: Analytical validation of different 
methods for determination of main acute phase proteins in canine samples [Abstract]. 
Available at: 
http://www.gla.ac.uk/faculties/vet/research/protein/04_segovia_2003/abstracts/ponencia
51.pdf. Accessed 13-9-2004. 
Matijatko,V. and N.Kucer, 2002: CRP concentration in dogs with uncomplicated and 
complicated babesiosis [Abstract]. Available at: 
http://www.gla.ac.uk/faculties/vet/research/protein/03_doorn_2002/abstracts/Razdorov.
html. Accessed 13-10-2004. 
Maudsley,S. and M.B.Pepys, 1987: Immunochemical cross-reactions between pentraxins of 
different species. Immunology 62, 17-22. 
McCarty,M., 1947: The occurence during acute infections of a protein not normally present in 
the blood. IV. Crystalization of the C-reactive protein. Journal of Experimental Medicine 
85, 491-498. 
McGrotty,Y.L., C.M.Knottenbelt, I.K.Ramsey, S.W.Reid and P.D.Eckersall, 2004: Evaluation of a 
rapid assay for canine C-reactive protein. Veterinary Record 154, 175-176. 
Mookerjea,S., J.Francis, D.Hunt, C.Y.Yang and A.Nagpurkar, 1994: Rat C-reactive protein 
causes a charge modification of LDL and stimulates its degradation by macrophages. 
Arteriosclerosis and Thrombosis 14, 282-287. 
Moshage,H., 1997: Cytokines and the hepatic acute phase response. Journal of Pathology 181, 
257-266. 
Murphy,T.M., L.L.Baum and K.D.Beaman, 1991: Extrahepatic transcription of human C-reactive 
protein. Journal of Experimental Medicine 173, 495-498. 
Ndung'u,J.M., P.D.Eckersall and F.W.Jennings, 1991: Elevation of the concentration of acute 
phase proteins in dogs infected with Trypanosoma brucei. Acta Tropica 49, 77-86. 
Nesbitt,G.H., L.M.Freeman and S.S.Hannah, 2003: Effect of n-3 fatty acid ratio and dose on 
clinical manifestations, plasma fatty acids and inflammatory mediators in dogs with 
pruritus. Veterinary Dermatology 14, 67-74. 
Onishi,T., H.Inokuma, K.Ohno, S.Soeda, K.Noguchi and K.Sasaki, 2000: C-reactive protein 
concentrations in normal and diseased dogs - measured by laser nephelometric 
immunoassay. Journal of the Japan Veterinary Medical Association 53, 595-601. 
Onishi,T., T.Shimizu and T.Kajikawa, 1994: Simple and efficient purification of C-reactive 
protein from canine serum. Journal of Veterinary Medical Science 56, 417-419. 
Osmand,A.P., B.Friedenson, H.Gewurz, R.H.Painter, T.Hofmann and E.Shelton, 1977: 
Characterization of C-reactive protein and the complement subcomponent C1t as 
_____________________________________________________________________ 
 126 
homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proceedings 
of the National Academy of Science of the United States of America 74, 739-743. 
Otabe,K., T.Ito, T.Sugimoto and S.Yamamoto, 2000: C-reactive protein (CRP) measurement in 
canine serum following experimentally-induced acute gastric mucosal injury. Laboratory 
Animals 34, 434-438. 
Otabe,K., T.Sugimoto, T.Jinbo, M.Honda, S.Kitao, S.Hayashi, M.Shimizu and S.Yamamoto, 
1998: Physiological levels of C-reactive protein in normal canine sera. Veterinary 
Research Communications 22, 77-85. 
Parra,M.D., S.Martínez-Subiela, M.Tuomola and J.J.Ceron, 2002: Evaluation of different 
monoclonal antibodies against human CRP in a TR-FIA for determination of canine 
CRP. Available at: 
http://www.gla.ac.uk/faculties/vet/research/protein/03_doorn_2002/abstracts/Ceron.html
. Accessed 13-9-2004. 
Parra,M.D., M.Tuomola, J.Cabezas-Herrera and J.J.Ceron, 2004: Use of a time-resolved 
immunofluorometric assay for determination of canine C-reactive protein concentrations 
in whole blood. American Journal of Veterinary Research [In Press]. 
Pepys,M.B. and M.L.Baltz, 1983: Acute phase proteins with special reference to C-reactive 
protein and related proteins (pentraxins) and serum amyloid A protein. In: Advances in 
immunology, 1 ed. (editors: Dixon,W.J. and H.G.Kunkel), Academic Press, New York, 
USA. pp. 141-212. 
Pepys,M.B. and G.M.Hirschfield, 2003: C-reactive protein: a critical update. Journal of Clinical 
Investigation 111, 1805-1812. 
Petersen,P.H., C.G.Fraser, L.Jørgensen, I.Brandslund, M.Stahl, E.M.S.Gowans, J.-C.Libeer 
and C.Ricós, 2002: Combination of analytical quality specifications based on biological 
within- and between-subject variation. Annals of Clinical Biochemistry 39, 543-550. 
Petersen,P.H., C.Ricos, D.Stoeckl, J.C.Libeer, H.Baadenhuijsen, C.G.Fraser and L.Thienpont, 
1996: Proposed guidelines for the internal quality control of analytical results in the 
medical laboratory. European Journal of Clinical Chemistry and Clinical Biochemistry 
34, 983-999. 
Pue,C.A., R.F.Mortensen, C.B.Marsh, H.A.Pope and M.D.Wewers, 1996: Acute phase levels of 
C-reactive protein enhance IL-1 beta and IL-1ra production by human blood monocytes 
but inhibit IL-1 beta and IL-1ra production by alveolar macrophages. Journal of 
Immunology 156, 1594-1600. 
Rikihisa,Y., S.Yamamoto, I.Kwak, Z.Iqbal, G.Kociba, J.Mott and W.Chichanasiriwithaya, 1994: 
C-reactive protein and alpha1-acid glycoprotein levels in dogs infected with Ehrlichia 
canis. Journal of Clinical Microbiology 32, 912-917. 
Riley,R.F. and M.K.Coleman, 1970: Isolation of C-reactive proteins of man monkey, rabbit and 
dog by affinity chromatography on phosphorylated cellulose. Clinica Chimica Acta 30, 
483-496. 
Riley,R.F. and W.Zontine, 1972: Further observations on the properties of dog C-reactive 
protein and the C-reactive protein response in the dog. Journal of Laboratory and 
Clinical Medicine 80, 698-703. 
_____________________________________________________________________ 
 127 
Robey,F.A. and T.Y.Liu, 1981: Limulin: a C-reactive protein from Limulus polyphemus. The 
Journal of Biological Chemistry 256, 969-975. 
Salonen,E.M., T.Vartio, K.Hedman and A.Vaheri, 1984: Binding of fibronectin by the acute 
phase reactant C-reactive protein. The Journal of Biological Chemistry 259, 1496-1501. 
Shephard,E.G., R.Anderson, O.Rosen, M.S.Myer, M.Fridkin, A.F.Strachan and F.C.de Beer, 
1990: Peptides generated from C-reactive protein by a neutrophil membrane protease. 
Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and 
chemotaxis. Journal of Immunology 145, 1469-1476. 
Shimada,T., Y.Ishida, M.Shimizu, M.Nomura, K.Kawato, K.Iguchi and T.Jinbo, 2002: Monitoring 
C-reactive protein in beagle dogs experimentally inoculated with Ehrlichia canis. 
Veterinary Research Communications 26, 171-177. 
Shrive,A.K., G.M.Cheetham, D.Holden, D.A.Myles, W.G.Turnell, J.E.Volanakis, M.B.Pepys, 
A.C.Bloomer and T.J.Greenhough, 1996: Three dimensional structure of human C-
reactive protein. Nature Structural Biology 3, 346-354. 
Siegel,J., A.P.Osmand, M.F.Wilson and H.Gewurz, 1975: Interactions of C-reactive protein with 
the complement system. II. C-reactive protein-mediated consumption of complement by 
poly-L-lysine polymers and other polycations. Journal of Experimental Medicine 142, 
709-721. 
Skinner,J.G., 2001: Special report. International standardization of acute phase proteins. 
Veterinary Clinical Pathology 30, 2-7. 
Spillmann,T., J.Korrell, A.Wittker, S.Börngen and M.Krüger, 2002: Serum canine pancreatic 
elastase and canine C-reactive protein for the diagnosis and prognosis of acute 
pancreatitis in dogs [Abstract]. Journal of Veterinary Internal Medicine 16, 635. 
Strandberg,T.E., H.Vanhanen and M.J.Tikkanen, 1999: Effect of statins on C-reactive protein in 
patients with coronary artery disease. Lancet 353, 118-119. 
Suffredini,A.F., G.Fantuzzi, R.Badolato, J.J.Oppenheim and N.P.O'grady, 1999: New insight 
into the biology of the acute phase response. Journal of Clinical Immunology 19, 203-
214. 
Tagata,K., S.Yokoyama, T.Ginbo, M.Honda, T.Okimura, M.Odakura, M.Nomura and 
S.Yamamoto, 1996: Quantitative capillary reversed passive latex agglutination test for 
C-reactive protein (CRP) in the dog. Veterinary Research Communications 20, 21-30. 
Taylor,A.W., N.-O.Ku and R.F.Mortensen, 1989: Both human IL-1 and IL-6 induce synthesis of 
C-reactive protein (CRP) by the PLC/PRF/5 hepatoma cell line. Annals of the New York 
Academy of Science 557, 532-533. 
Tillet,W.S. and T.Francis, 1930: Serological reactions in pneumonia with a non-protein somatic 
fraction of pneumococcus. Journal of Experimental Medicine 52, 561-571. 
Uhlenbruck,G., J.Solter and E.Janssen, 1981: [New reaction mechanisms of C-reactive protein 
(CRP) and related proteins (author's translation)]. Journal of Clinical Chemistry and 
Clinical Biochemistry 19, 1201-1208. 
_____________________________________________________________________ 
 128 
Vogelaar,S.A., D.Posthuma, D.Boomsma and C.Kluft, 2002: Blood sample stability at room 
temperature for counting red and white blood cells and platelets. Vascular 
pharmacology 39, 123-125. 
Volanakis,J.E., 2001: Human C-reactive protein: expression, structure, and function. Molecular 
Immunology 38, 189-197. 
Volanakis,J.E. and K.W.Wirtz, 1979: Interaction of C-reactive protein with artificial 
phosphatidylcholine bilayers. Nature 281, 155-157. 
Wannemacher,R.W., Jr., R.S.Pekarek, W.L.Thompson, R.T.Curnow, F.A.Beall, T.V.Zenser, 
F.R.DeRubertis and W.R.Beisel, 1975: A protein from polymorphonuclear leukocytes 
(LEM) which affects the rate of hepatic amino acid transport and synthesis of acute-
phase globulins. Endocrinology 96, 651-661. 
Westgard,J.O., 2001: Six sigma quality design and control - desirable precision and requisite 
QC for laboratory measurement processes. Westgard QC, Inc., Madison, WI, USA. pp. 
1-296. 
Westgard,J.O., 2003: Internal quality control: planning and implementation strategies. Annals of 
Clinical Biochemistry 40, 593-611. 
Woollard,K.J., D.C.Phillips and H.R.Griffiths, 2002: Direct modulatory effect of C-reactive protein 
on primary human monocyte adhesion to human endothelial cells. Clinical and 
Experimental Immunology 130, 256-262. 
Yamamoto,S., S.Miyaji, N.Abe, K.Otabe, E.Furukawa and M.Naiki, 1993a: Canine C-reactive 
protein (CRP) does not share common antigenicity with human CRP. Veterinary 
Research Communications 17, 259-266. 
Yamamoto,S., T.Shida, M.Honda, Y.Ashida, Y.Rikihisa, M.Odakura, S.Hayashi, M.Nomura and 
Y.Isayama, 1994a: Serum C-reactive protein and immune responses in dogs inoculated 
with Bordetella bronchiseptica (phase I cells). Veterinary Research Communications 18, 
347-357. 
Yamamoto,S., T.Shida, S.Miyaji, H.Santsuka, H.Fujise, K.Mukawa, E.Furukawa, T.Nagae and 
M.Naiki, 1993b: Changes in serum C-reactive protein levels in dogs with various 
disorders and surgical traumas. Veterinary Research Communications 17, 85-93. 
Yamamoto,S., T.Shida, T.Okimura, K.Otabe, M.Honda, Y.Ashinda, E.Furukawa, M.Sarikaputi 
and M.Naiki, 1994b: Determination of C-reactive protein in serum and plasma from 
healthy dogs and dogs with pneumonia by ELISA and slide reversed passive latex 
agglutination test. Veterinary Quarterly 16, 74-77. 
Yamamoto,S., K.Tagata, H.Nagahata, Y.Ishikawa, M.Morimatsu and M.Naiki, 1992: Isolation of 
canine C-reactive protein and characterization of its properties. Veterinary Immunology 
and Immunopathology 30, 329-339. 
Yamamoto,S., K.Tagata, K.Otabe and T.Shida, 1993c: Serum levels of C-reactive protein in 
dogs and simple techniques for its measurement. Journal of the Japan Veterinary 
Medical Association 46, 870-873. 
_____________________________________________________________________ 
 129 
Yamashita,K., T.Fujinaga, T.Miyamoto, T.Hagio, Y.Izumisawa and T.Kotani, 1994: Canine acute 
phase response: relationship between serum cytokine activity and acute phase protein 
in dogs. Journal of Veterinary Medical Science 56, 487-492. 
Zouki,C., M.Beauchamp, C.Baron and J.G.Filep, 1997: Prevention of In vitro neutrophil 
adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and 
peptides derived from C-reactive protein. Journal of Clinical Investigation 100, 522-529. 
Zweig,M.H. and E.A.Robertson, 1982: Why we need better test evaluations. Clinical Chemistry 
28, 1272-1276. 
 
 
_____________________________________________________________________ 
 130 
 
